UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2002
or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Commission File Number: 000-22313
AMERIPATH, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 65-0642485
---------------------------------------- -------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
7289 Garden Road, Suite 200,
Riviera Beach, Florida 33404
---------------------------------------- -------------------
(Address of principal executive offices) (Zip Code)
(561) 845-1850
(Registrant's telephone number, including area code)
NOT APPLICABLE
(Former name, former address and formal fiscal year,
if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [X] No [ ]
The registrant had 30,658,204 shares of common stock, $.01 par value,
outstanding as of August 5, 2002.
AMERIPATH, INC.AND SUBSIDIARIES
1
QUARTERLY REPORT ON FORM 10-Q
INDEX
PAGE
-----
PART I--FINANCIAL INFORMATION
Item 1. Financial Statements
Condensed Consolidated Balance Sheets as of June 30, 2002 (Unaudited) and
December 31, 2001...................................................................... 3
Condensed Consolidated Statements of Income for the Three and Six Months Ended June 30,
2002 and 2001 (Unaudited).............................................................. 4
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June
30, 2002 and 2001 (Unaudited).......................................................... 5
Notes to Condensed Consolidated Financial Statements (Unaudited)....................... 6-12
Item 2. Management's Discussion and Analysis of Financial Condition and Results of
Operations............................................................................. 13-39
Item 3. Quantitative and Qualitative Disclosures About Market Risk............................. 39
PART II--OTHER INFORMATION
Item 1. Legal Proceedings...................................................................... 40
Item 2. Changes in Securities and Use of Proceeds.............................................. 40
Item 4. Submission of Matters to Vote of Security Holders...................................... 40
Item 6. Exhibits and Reports on Form 8-K....................................................... 41
SIGNATURES............................................................................................. 42
2
PART I--FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
AMERIPATH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)
JUNE 30, DECEMBER 31,
2002 2001
------------ ------------
(UNAUDITED)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents ..................... $ 1,768 $ 4,808
Accounts receivable, net ...................... 89,039 81,595
Inventories ................................... 1,431 1,892
Other current assets .......................... 15,505 15,780
------------ ------------
Total current assets ...................... 107,743 104,075
------------ ------------
PROPERTY AND EQUIPMENT, NET ...................... 24,392 24,118
------------ ------------
OTHER ASSETS:
Goodwill, net ................................. 250,077 216,222
Identifiable intangibles, net ................. 254,088 253,562
Other ......................................... 6,980 6,485
------------ ------------
Total other assets ........................ 511,145 476,269
------------ ------------
Total Assets ..................................... $ 643,280 $ 604,462
============ ============
LIABILITIES AND COMMON STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued expenses ......... $ 39,452 $ 42,876
Current portion of long-term debt ............. 642 469
Other current liabilities ..................... 3,662 3,910
------------ ------------
Total current liabilities ................. 43,756 47,255
------------ ------------
LONG-TERM LIABILITIES:
Revolving loan ................................ 98,550 90,000
Long-term debt ................................ 2,743 2,853
Other liabilities ............................. 1,650 2,690
Deferred tax liability ........................ 65,554 62,474
------------ ------------
Total liabilities ......................... 168,497 158,017
------------ ------------
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Common stock .................................. 306 302
Additional paid-in capital .................... 319,590 314,168
Retained earnings ............................. 111,131 84,720
------------ ------------
Total stockholders' equity ................ 431,027 399,190
------------ ------------
Total Liabilities and Stockholders' Equity ....... $ 643,280 $ 604,462
============ ============
The accompanying notes are an integral part of these unaudited financial
statements.
3
AMERIPATH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)
Three Months Ended Six Months Ended
June 30, June 30,
--------------------------- ---------------------------
2002 2001 2002 2001
------------ ------------ ------------ ------------
NET REVENUES:
Net patient service revenue $ 114,131 $ 97,335 $ 219,933 $ 189,059
Net management service revenue 6,608 7,717 13,698 14,738
------------ ------------ ------------ ------------
Total net revenues 120,739 105,052 233,631 203,797
------------ ------------ ------------ ------------
OPERATING COSTS AND EXPENSES:
Cost of Services:
Net patient service revenue 55,169 44,189 105,409 87,777
Net management service revenue 3,716 5,201 7,816 10,045
------------ ------------ ------------ ------------
Total cost of services 58,885 49,390 113,225 97,822
Selling, general and administrative expenses 20,641 18,168 40,690 35,386
Provision for doubtful accounts 14,440 12,548 28,114 23,206
Amortization expense 2,803 4,654 5,585 9,180
Merger-related charges -- -- -- 7,103
------------ ------------ ------------ ------------
Total operating costs and expenses 96,769 84,760 187,614 172,697
------------ ------------ ------------ ------------
INCOME FROM OPERATIONS 23,970 20,292 46,017 31,100
------------ ------------ ------------ ------------
OTHER INCOME (EXPENSE):
Interest expense (1,078) (4,695) (2,131) (9,437)
Other, net 46 120 132 144
------------ ------------ ------------ ------------
Total other expense (1,032) (4,575) (1,999) (9,293)
------------ ------------ ------------ ------------
INCOME BEFORE INCOME TAXES 22,938 15,717 44,018 21,807
PROVISION FOR INCOME TAXES 9,175 6,570 17,607 9,419
------------ ------------ ------------ ------------
NET INCOME $ 13,763 $ 9,147 $ 26,411 $ 12,388
============ ============ ============ ============
BASIC EARNINGS PER COMMON SHARE:
Basic earnings per common share $ 0.45 $ 0.36 $ 0.87 $ 0.50
============ ============ ============ ============
Basic weighted average shares outstanding 30,518 25,092 30,419 24,951
============ ============ ============ ============
DILUTED EARNINGS PER COMMON SHARE:
Diluted earnings per common share $ 0.44 $ 0.35 $ 0.85 $ 0.48
============ ============ ============ ============
Diluted weighted average shares outstanding 31,232 26,139 31,230 26,065
============ ============ ============ ============
The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
4
AMERIPATH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(UNAUDITED)
Six Months Ended
June 30,
-----------------------
2002 2001
---------- ----------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $ 26,411 $ 12,388
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization 9,461 12,497
Loss on disposal of assets (15) (38)
Deferred income taxes (3,500) (2,600)
Provision for doubtful accounts 28,114 23,206
Merger-related charges -- 7,103
Changes in assets and liabilities (net of effects of acquisitions):
Increase in accounts receivable (34,752) (34,507)
Decrease in inventories 461 10
Decrease in other current assets 275 743
Increase in other assets (300) (239)
Increase in accounts payable and accrued expenses 165 326
Merger-related charges paid (87) (3,099)
---------- ----------
Net cash provided by operating activities 26,233 15,790
---------- ----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment (3,755) (4,591)
Merger-related charges paid (1,301) (402)
Cash paid for acquisitions and acquisition costs, net of cash acquired (9,321) (164)
Payments of contingent notes (27,429) (23,781)
---------- ----------
Net cash used in investing activities (41,806) (28,938)
---------- ----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options and warrants 2,158 2,235
Debt issuance costs (220) (94)
Principal payments on long-term debt (173) (706)
Net borrowings under revolving loan 8,550 11,784
Tax benefits from stock options 2,218 --
---------- ----------
Net cash provided by financing activities 12,533 13,219
---------- ----------
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (3,040) 71
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 4,808 2,418
---------- ----------
CASH AND CASH EQUIVALENTS, END OF PERIOD $ 1,768 $ 2,489
========== ==========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Contingent stock issued $ 822 $ 822
========== ==========
The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
5
AMERIPATH, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE 1--BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements,
which include the accounts of AmeriPath, Inc. and its Subsidiaries
(collectively, "AmeriPath" or the "Company"), have been prepared in accordance
with accounting principles generally accepted in the United States ("GAAP") for
interim financial reporting and the instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, the financial statements do not include all of the
information and notes required by GAAP for complete financial statements. In the
opinion of management, such interim financial statements contain all adjustments
(consisting of normal recurring items) considered necessary for a fair
presentation of the Company's financial position, results of operations and cash
flows for the interim periods presented. The results of operations and cash
flows for any interim periods are not necessarily indicative of results which
may be reported for the year ended December 31, 2002.
The accompanying unaudited interim financial statements should be read in
conjunction with the audited consolidated financial statements, and the notes
thereto, included in the Company's Annual Report on Form 10-K for the year ended
December 31, 2001, as filed with the Securities and Exchange Commission.
In order to maintain consistency and comparability between periods
presented, certain amounts have been reclassified in order to conform with the
financial statement presentation of the current period.
RECENT ACCOUNTING PRONOUNCEMENTS
In July 2001, the FASB issued Statement of Financial Accounting Standards
No. 141, "Business Combinations" ("SFAS 141"). SFAS 141 requires the purchase
method of accounting for business combinations initiated after June 30, 2001 and
eliminates the pooling-of-interests method. The Company adopted the provisions
of SFAS 141 on January 1, 2002 with no significant impact on its financial
statements.
In June 2001, the FASB issued Statement of Financial Accounting Standards
No. 142, "Goodwill and Other Intangible Assets" ("SFAS 142"), which was
effective January 1, 2002. SFAS 142 requires, among other things, the
discontinuance of goodwill amortization. In addition, the standard includes
provisions for the reclassification of certain existing recognized intangibles
as goodwill, reassessment of the useful lives of existing recognized
intangibles, reclassification of certain intangibles out of previously reported
goodwill and the identification of reporting units for purposes of assessing
potential future impairments of goodwill. SFAS 142 also requires us to complete
a transitional goodwill impairment test six months from the date of adoption.
For the second quarter of 2001 and for the year ending December 31, 2001,
goodwill amortization was approximately $1.8 million and $7.4 million,
respectively. The Company has stopped amortizing goodwill effective January 1,
2002. In addition, due to the fact that a portion of this goodwill was not tax
deductible, our effective tax rate was greater than the statutory rate. The
elimination of the goodwill amortization, including nondeductible goodwill
amortization, from future periods should result in a 1% to 2% reduction in our
effective tax rate.
In June 2001, the FASB issued SFAS No. 143, "Accounting for Asset
Retirement Obligations" ("SFAS 143"). SFAS 143 addresses financial accounting
and reporting for obligations associated with the retirement of tangible
long-lived assets and the associated asset retirement costs. It applies to legal
obligations associated with the retirement of long-lived assets that result from
the acquisition, construction, development, and (or) the normal operation of a
long-lived asset, except for certain obligations of lessees. The provisions of
SFAS 143 will be effective for fiscal years beginning after June 15, 2002;
however early application is permitted. The Company is currently evaluating the
implications of adoption of SFAS 143 on its financial statements.
AMERIPATH, INC. AND SUBSIDIARIES
6
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (CONTINUED)
In August 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or
Disposal of Long-Lived Assets" ("SFAS 144"). SFAS 144 provides accounting
guidance for financial accounting and reporting for impairment or disposal of
long-lived assets. SFAS 144 supersedes SFAS 121. SFAS 144 is effective for the
Company in fiscal 2002. Management does not currently believe that the
implementation of SFAS 144 will have a material impact on the Company's
financial condition or results of operations.
NOTE 2--ACQUISITIONS
During the first six months of 2002, the Company acquired a lab operation
in California and purchased the remaining interest of the Denver, Colorado
operation which was previously managed by the Company under a management
services agreement. Total consideration paid consisted of cash, common stock,
and consideration in the form of contingent notes and the assumption of certain
liabilities. In addition, during the second quarter of 2002 and the six months
ended June 30, 2002, the Company made contingent note payments of $9.8 million
and $27.4 million, respectively, relating to previous acquisitions.
NOTE 3--GOODWILL AND IDENTIFIABLE INTANGIBLE ASSETS
Intangible assets and the related accumulated amortization and amortization
periods are set forth below (dollars in thousands):
JUNE 30, 2002
JUNE 30, DECEMBER 31, AMORTIZATION PERIODS
2002 2001 (YEARS)
---------- ------------ -----------------------
WEIGHTED
RANGE AVERAGE
---------- -----------
Hospital contracts........... $ 215,944 $ 211,638 25-40 32.2
Physician client lists....... 68,732 66,646 10-30 20.8
Laboratory contracts......... 4,543 4,543 10 10.0
Management service agreement 11,039 11,379 25 25.0
---------- ------------
300,258 294,206
Accumulated amortization..... (46,170) (40,644)
---------- ------------
Identifiable intangibles, net $ 254,088 $ 253,562
========== ============
Goodwill..................... $ 273,275 $ 239,361
Accumulated amortization..... (23,198) (23,139)
---------- ------------
Goodwill, net................ $ 250,077 $ 216,222
========== ============
The weighted average amortization period for identifiable intangible assets
is approximately 29 years.
The Company adopted the provisions of FASB Statement No. 141 as of January
1, 2002. FASB Statement No. 142 further clarifies the criteria to recognize
intangible assets separately from goodwill and promulgates that goodwill and
certain intangible assets not be amortized. Instead, these assets will be
reviewed for impairment annually with any related losses recognized in earnings
when incurred. The Company adopted the provisions of FASB Statement No. 142 as
of January 1, 2002. Accordingly, the Company completed the transitional
impairment test of goodwill and indefinite lived intangible assets during the
second quarter of 2002. Based on the results of this test, the Company
determined that there was no impairment of goodwill or indefinite lived
intangible assets as of January 1, 2002.
AMERIPATH, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (CONTINUED)
7
The following reconciliation adjusts net income for amortization expense related
to goodwill that is no longer amortized under the provision of FASB Statement
No. 142:
Three Months Ended Six Months Ended
June 30, 2001 June 30, 2001
------------------ ----------------
(Unaudited, amounts in thousands, except per share data)
Earnings effect:
Net income, as reported $ 9,147 $ 12,388
Goodwill amortization, net of tax 1,344 2,688
------------------ ----------------
Adjusted net income 10,491 $ 15,076
================== ================
EPS effect:
Net icome, as reported $ .35 $ .48
Goodwill amortization .05 .10
------------------ ----------------
Adjusted net income $ .40 $ .58
================== ================
Diluted shares outstanding 26,139 26,065
================== ================
NOTE 4--MERGER-RELATED CHARGES
In connection with the Inform DX merger and other previous acquisitions,
the Company has recorded specific reserves for transaction costs,
employee-related costs (including severance agreement payouts) and various exit
costs associated with the consolidation of certain operations, including the
elimination of duplicate facilities and certain exit and restructuring costs. As
part of the Inform DX acquisition, the Company is closing or consolidating
certain facilities.
A reconciliation of the activity for the six months ended June 30, 2002
with respect to the merger-related reserves is as follows:
BALANCE STATEMENT OF BALANCE
DECEMBER 31, OPERATIONS JUNE 30,
2001 CHARGES PAYMENTS 2002
------------ ------------ ---------- ----------
Transaction costs................................... $ 116 $ -- $ (87) $ 29
Employee termination costs.......................... 3,432 -- (965) 2,467
Lease commitments................................... 2,165 -- (310) 1,855
Other exit costs.................................... 160 -- (26) 134
------------ ------------ ---------- ----------
Total.......................................... 5,873 $ -- $ (1,388) 4,485
============ ==========
Less: portion included in other current liabilities. (3,183) (2,835)
------------ ----------
Total included in other liabilities............ $ 2,690 $ 1,650
============ ==========
NOTE 5--MARKETABLE SECURITIES
The Company accounts for investments in certain debt and equity securities
under the provisions of Statement of Financial Accounting Standards No. 115 (
"SFAS No. 115 "), "Accounting for Certain Debt and Equity Securities ". Under
SFAS No. 115, the Company must classify its debt and marketable equity
securities in one of three categories: trading, available-for-sale, or
held-to-maturity.
AMERIPATH, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (CONTINUED)
8
In September 2000, the Company made a $1 million investment in Genomics
Collaborative, Inc ("GCI") for which it received 333,333 shares of Series D
Preferred Stock, par value $0.01. The shares of GCI Series D Preferred Stock are
convertible into shares of GCI common stock on a one-for-one basis and are
redeemable after 2005 at $3.00 per share at the option of the holder. GCI is a
privately held, start-up, company which has a history of operating losses. As of
June 30, 2002, it appears that GCI has sufficient cash to fund operations for
the next twelve months. In the event that they are unable to become profitable
and/or raise additional funding, it could result in an impairment of the
Company's investment. This available for sale security is recorded at its
estimated fair value, which approximates cost, and is classified as other assets
on the Company's consolidated balance sheet. At June 30, 2002, there were no
unrealized gains or losses associated with this investment.
NOTE 6--COMMITMENTS AND CONTINGENCIES
Medical Malpractice-Through June 30, 2002, the Company was insured for
medical malpractice risks on a claims made basis. The Company has recorded an
estimate of its liabilities for claims incurred but not reported. Such
liabilities are not discounted. Effective July 1, 1999, the Company changed its
medical malpractice carrier and the Company is currently in a dispute with its
former insurance carrier on an issue related to the applicability of surplus
insurance coverage. The Company believes that an unfavorable resolution, if any,
of such dispute would not have a material adverse effect on the Company's
financial position or results of operations.
Effective July 1, 2002, the Company formed a captive insurance company to
partially self-insure for medical malpractice. The captive combined with excess
coverage will provide insurance on a per claim basis. The Company does not have
any aggregate excess stop loss protection. Accruals for settlement costs, claims
expenses and incurred but not reported claims will be made based on actuarial
estimates. We anticipate significant increased cost and risk retention by the
Company in connection with this program. Actual costs in future periods could
differ materially from actuarial studies depending on the frequency and severity
of actual claims experience.
Self-insured health benefits-Effective August 1, 2002, health care benefits
were provided under a company-sponsored self-insured plan. The Company will
record its estimate of the ultimate cost of, and reserves for, health care
benefits based on computations using the company's loss history as well as
industry statistics. Furthermore, in determining its reserves, the Company will
include reserves for estimated claims incurred but not reported.
The ultimate cost of health care benefits will depend on actual costs
incurred to settle the claims and may differ from the amounts reserved by the
Company for those claims.
Healthcare Regulatory Environment and Reliance on Government Programs-The
healthcare industry in general, and the services that the Company provides, are
subject to extensive federal and state laws and regulations. Additionally, a
significant portion of the Company's net revenue is from payments by
government-sponsored health care programs, principally Medicare and Medicaid,
and is subject to audit and adjustments by applicable regulatory agencies.
Failure to comply with any of these laws or regulations, the results of
increased regulatory audits and adjustments, or changes in the interpretation of
the coding of services or the amounts payable for the Company's services under
these programs could have a material adverse effect on the Company's financial
position and results of operations. The Company's operations are continuously
subject to review and inspection by regulatory authorities.
AMERIPATH, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (CONTINUED)
We have recently received subpoenas issued by the United States Attorney's
office in Tampa, Florida seeking information with respect to an investigation
relating to Medicare billing and possible financial inducements in connection
with a Florida physician who is not an AmeriPath pathologist but is a client of
AmeriPath. We are providing information to the United States Attorney's office
and intend to cooperate in the investigation. We also are
9
conducting our own internal investigation of the matter. It is not possible at
this point in the investigation to determine whether the government will pursue
action against AmeriPath or to assess the merits of possible defenses AmeriPath
might have to any such action. Accordingly, no assurances can be given regarding
the ultimate outcome of the investigation.
NOTE 7--EARNINGS PER SHARE
Earnings per share is computed and presented in accordance with Statement
of Financial Accounting Standards ("SFAS") No. 128, "Earnings Per Share." Basic
earnings per share, which excludes the effects of any dilutive common equivalent
shares that may be outstanding, such as shares issuable upon the exercise of
stock options and warrants, is computed by dividing income attributable to
common stockholders by the weighted average number of common shares outstanding
for the respective periods. Diluted earnings per share gives effect to the
potential dilution that could occur upon the exercise of certain stock options
and warrants that were outstanding at various times during the respective
periods presented. The dilutive effects of stock options and warrants are
calculated using the treasury stock method.
Basic and diluted earnings per share for the respective periods are set
forth in the table below (amounts in thousands, except per share amounts):
Three Months Ended Six Months Ended
June 30, June 30,
--------------------- ---------------------
2002 2001 2002 2001
--------- --------- --------- ---------
Earnings Per Common Share:
Net income $ 13,763 $ 9,147 $ 26,411 $ 12,388
========= ========= ========= =========
Basic earnings per common share $ 0.45 $ 0.36 $ 0.87 $ 0.50
========= ========= ========= =========
Diluted earnings per common share $ 0.44 $ 0.35 $ 0.85 $ 0.48
========= ========= ========= =========
Basic weighted average shares outstanding 30,518 25,092 30,419 24,951
Effect of dilutive stock options and warrants 714 1,047 811 1,114
--------- --------- --------- ---------
Diluted weighted average shares outstanding 31,232 26,139 31,230 26,065
========= ========= ========= =========
Certain shares of common stock that are issuable upon the exercise of
options have been excluded from the per share calculation because their effect
would be anti-dilutive.
AMERIPATH, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (CONTINUED)
NOTE 8--COMPREHENSIVE INCOME
10
The Company adopted Statement of Financial Accounting Standards No. 130,
"Reporting Comprehensive Income" ("SFAS 130"), which requires the Company to
report and display certain information related to comprehensive income. As of
June 30, 2002 and December 31, 2001 net income equaled comprehensive income.
NOTE 9--SEGMENT REPORTING
The Company has two reportable segments, Owned and Managed operations. The
segments were determined based on the type of service and customer. Owned
operations provide anatomic pathology services to hospitals and referring
physicians, while under the management relationships the Company provides
management services to the affiliated physician groups. The accounting policies
of the segments are the same as those described in the summary of accounting
policies. The Company evaluates performance based on revenue and income before
amortization of intangibles, merger-related charges, interest expense, other
income and expense and income taxes ("Segment Income from Operations"). In
addition to the business segments above, the Company evaluates certain corporate
expenses which are not allocated to the business segments.
The following is a summary of the financial information for the three and
six months ended June 30, 2002 and 2001, for the business segments and
corporate.
Three months ended June 30, Six months ended June 30,
--------------------------- ---------------------------
2002 2001 2002 2001
------------ ------------ ------------ ------------
Owned
Net patient service revenue $ 114,131 $ 97,335 $ 219,933 $ 189,059
Income from operations 33,178 30,488 64,496 57,814
Segment assets 449,524 301,498
Managed
Net management service revenue $ 6,608 $ 7,717 $ 13,698 $ 14,738
Income from operations 908 1,152 1,689 2,281
Segment assets 23,101 21,950
Corporate
Operating loss $ (7,313) $ (6,694) $ (14,583) $ (12,712)
Segment assets 207,955 294,489
Elimination of intercompany accounts (37,300) (30,063)
AMERIPATH, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (CONTINUED)
NOTE 10--SUBSEQUENT EVENTS
Subsequent to June 30, 2002, the Company paid approximately $1.0 million
relating to contingent notes issued in connection with previous acquisitions,
which has been recorded as additional purchase price and an increase in
goodwill.
In July 2002, the Company acquired O'Quinn Medical Pathology Association,
Inc., a full service anatomic pathology operation located in Augusta, Georgia.
11
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
OVERVIEW
We are one of the leading national providers of anatomic pathology
services. The more than 400 pathologists in our owned and managed operations
provide medical diagnostic services in outpatient laboratories owned or managed
by us, in hospitals, and in ambulatory surgery centers. Under our ownership or
employment model, we have a controlling equity (i.e., voting) interest or a
controlling financial interest in pathology operations. We refer to these
operations as our owned operations. Under our management or equity model, we
operate pathology laboratories under long-term management services agreements.
We refer to these as our managed operations. Under the management services
agreements, we provide facilities and equipment as well as administrative and
technical support for the managed operations. As of June 30, 2002, we had five
managed operations. When we refer to "companies" generally, we mean our owned
and managed operations as a group.
12
As of June 30, 2002, our companies had contracts or business relationships
with more than 200 hospitals pursuant to which we manage their clinical
pathology and other laboratories and provide professional pathology services.
The majority of these hospital contracts and relationships are exclusive
provider relationships. We also have 14 primary outpatient laboratories and
numerous satellite labs where we are licensed to perform outpatient pathology
services.
Generally, we manage and control all of the non-medical functions of the
companies, including:
. recruiting, training, employing and managing the technical and support
staff;
. developing, equipping and staffing laboratory facilities;
. establishing and maintaining courier services to transport specimens;
. negotiating and maintaining contracts with hospitals, national
clinical laboratories and managed care organizations and other payors;
. providing financial reporting and administration, clerical,
purchasing, payroll, billing and collection, information systems,
sales and marketing, risk management, employee benefits, legal, tax
and accounting services;
. maintaining compliance with applicable laws, rules and regulations;
and
. with respect to our ownership and operation of outpatient anatomic
pathology laboratories, providing slide preparation and other
technical services.
RECENT DEVELOPMENTS
Acquisitions-During the first six months of 2002, the Company has made two
acquisitions. The first acquisition, in February 2002, was an operation located
in Denver, Colorado which was previously managed by the Company under a
management services agreement. The second acquisition, in April 2002, was a full
service anatomic pathology laboratory located in Irvine, California. The total
consideration paid by the Company in connection with these acquisitions included
cash, common stock, consideration in the form of contingent notes and the
assumption of certain liabilities. In addition, during the first six months of
2002, the Company made contingent note payments of $27.4 million relating to
previous acquisitions. In July 2002, the Company acquired O'Quinn Medical
Pathology Association, Inc., a full service anatomic pathology located in
Augusta, Georgia. The combined estimated bookable revenue in 2002 related to
these acquisitions is $15 million.
Malpractice Insurance - In late June 2002, we completed the renewal of our
medical malpractice insurance program for the policy year beginning July 1,
2002. In connection with our renewal we were unable to obtain traditional lines
of coverage similar to previous coverage. As a result, we formed a captive
insurance company to partially self-insure our medical malpractice risk. Under
the captive structure we will retain more risk for medical malpractice costs,
including settlements and claims expense, than our previous coverage. The
captive insurance company and excess policies provide malpractice insurance on a
per-claim basis. We have no aggregate excess stop loss protection. Based on
actuarial estimates, our medical malpractice costs for the policy year beginning
July 1, 2002 are expected to increase $6.0 to $8.0 million over the previous
year. Although we have estimated this increase based on actuarial studies,
actual costs could exceed these amounts depending on the frequency and severity
of our actual claims experience.
2003 Medicare Reimbursement - On June 28, 2002, the Department of Health
and Human Services' Centers for Medicare and Medicaid Services ("CMS") issued
proposed revisions to payment policies under the physician fee schedule for
calendar year 2003. Under the proposed rule, reimbursement from Medicare for
anatomic pathology services would decrease in 2003. The proposed rule calls for
a 4.4% reduction in the physician conversion factor from $36.92 to $34.61. In
addition, the proposed rule would reduce the amount of money paid to
pathologists for
13
practice and overhead expenses through a reduction in the pathologists' relative
value unit factors. Based on the proposed regulation, and our 2002 estimated
volume and mix, we estimate that net revenue would be negatively impacted by
$10.0 million to $11.0 million per year, or 2% of our total estimated net
revenue. Currently, there is a Medicare reform bill that has already passed two
house committees that would increase the physician conversion factor for 2003 by
2 %. If this proposed legislation passes our estimated negative impact on net
revenue would be reduced to $3.0 to $4.0 million per year. These proposals are
subject to comment and the final regulations, which are due to be published in
the fourth quarter of 2002, may differ and have other positive or negative
impacts on our future net revenue.
National Clinical Labs - As previously disclosed in the first quarter of
2002, our Philadelphia operation experienced substantial declines in volume from
Quest Diagnostics, Incorporated ("Quest"). This decline continued in the second
quarter and we experienced declines in Quest volume in Southern California.
Subsequent to June 30, 2002, our Orlando operation experienced a reduction in
Quest cytology volume. For the second quarter, Quest revenue was approximately
$7.0 million. Although we have not received formal notification of contract
termination, we believe that, over the next 12 to 18 months, Quest will
internalize the anatomic pathology work currently subcontracted to us. Although
there can be no assurance, we believe that, through directed marketing and
managed care efforts, we will be able to replace, over the next 24 months, 50%
to 75% of this unit volume with retail business at higher reimbursement rates.
This transition away from our largest single outpatient customer could result in
earnings different than current expectations due to changes in timing of the
transition, higher unit costs due to excess capacity, lack of managed care
penetration and/or the degree of success in our marketing efforts. In addition,
we are currently assessing the potential impairment of identifiable intangible
assets, specifically lab contracts. In the event it is determined that these
intangibles are impaired, we would record an impairment charge. As of June 30,
2002, we had net intangibles assets related to lab contracts of $2.7 million. In
addition, we may need to reevaluate the goodwill of the affected reporting units
for possible impairment.
Regulatory Matters - We have recently received subpoenas issued by the
United States Attorney's office in Tampa, Florida seeking information with
respect to an investigation relating to Medicare billing and possible financial
inducements in connection with a Florida physician who is not an AmeriPath
pathologist but is a client of AmeriPath. We are providing information to the
United States Attorney's office and intend to cooperate in the investigation. We
also are conducting our own internal investigation of the matter. It is not
possible at this point in the investigation to determine whether the government
will pursue action against AmeriPath or to assess the merits of possible
defenses AmeriPath might have to any such action. Accordingly, no assurances can
be given regarding the ultimate outcome of the investigation.
SOURCES OF NET REVENUE
We derive our net revenue primarily from our owned and managed operations.
Net revenue was comprised of net patient service revenue from our owned
operations and net management service revenue from our managed operations.
The percent of our net revenue from outpatient and inpatient pathology and
management services is presented below. The type and mix of business among these
three categories, which can change from period to period as a result of new
acquisitions and other factors, may change our ratio of operating costs to net
revenue, particularly the provision for doubtful accounts as discussed below in
our results of operations.
THREE MONTHS SIX MONTHS
ENDED JUNE ENDED JUNE
30, 30,
------------ ----------
2002 2001 2002 2001
---- ---- ---- ----
Revenue Type
Outpatient........................ 50% 47% 49% 45%
Inpatient......................... 45% 46% 45% 48%
Management service revenues....... 5% 7% 6% 7%
14
NET PATIENT REVENUES
The majority of services furnished by our pathologists are anatomic
pathology diagnostic services. We typically bill government programs,
principally Medicare and Medicaid, indemnity insurance companies, managed care
organizations, national clinical laboratories, physicians and patients. Net
patient revenue differs from amounts billed for services due to:
. Medicare and Medicaid reimbursements at annually established rates;
. payments from managed care organizations at discounted fee-for-service
rates;
. negotiated reimbursement rates with national clinical laboratories and
other third-party payors; and
. other discounts and allowances.
In many instances, the national clinical laboratories contract directly
under capitated agreements with managed care organizations to provide clinical
as well as anatomic pathology services. We, in turn, subcontract with national
clinical laboratories to provide anatomic pathology services at a discounted
fee-for-service rate and previously attempted to increase the number of such
subcontracts to increase test volume. As discussed in Recent Developments, we
expect revenue from certain national clinical laboratories to decline in future
periods. Historically, net patient service revenue from capitated contracts has
represented an insignificant amount of total net patient service revenue.
However, we may be required to enter into more capitated arrangements in order
to compete effectively for managed care contracts in the future.
Virtually all of our net patient service revenue is derived from charging
for services on a fee-for-service basis. Accordingly, we assume the financial
risk related to collection, including potential uncollectability of accounts,
long collection cycles for accounts receivable and delays in reimbursement by
third-party payors, such as governmental programs, private insurance plans and
managed care organizations. Increases in write-offs of doubtful accounts, delays
in receiving payments or potential retroactive adjustments and penalties
resulting from audits by payors may require us to borrow funds to meet current
obligations or may otherwise have a material adverse effect on our financial
condition and results of operations.
In addition to services billed on a fee-for-service basis, our
hospital-based pathologists generally have supervision and oversight
responsibility for their roles as Medical Directors of the hospitals' clinical,
microbiology and blood banking operations. In some cases, we bill non-Medicare
patients according to a fee schedule for what is referred to as clinical
professional component ("CPC") charges. Our historical collection experience for
CPC charges is significantly lower than other anatomic pathology charges. For
example, one of our billing operations collects approximately 35% of net charges
for hospital CPC services compared to 70% for hospital anatomic pathology
services. This rate translates to a 50% bad debt rate for CPC charges and
increases our overall bad debt percentage. For Medicare patients, the
pathologist is typically paid a director's fee or a "Part A" fee by the
hospital. Hospitals and third-party payors are continuing to increase pressure
to reduce our revenue from CPC and "Part A" fees, and in the future we may
sustain substantial decreases in this revenue source or experience further
deterioration in CPC collectibility. In the event that hospitals and third party
payors are successful in reducing these sources of revenue, without
corresponding price increases for other services, our profits will be negatively
impacted since the majority of the costs supporting these revenues are fixed
costs in the form of physicians expense.
Approximately 20% of our collections for the six months ended June 2002
were from government-sponsored health care programs, principally Medicare and
Medicaid, and is subject to audit and adjustments by applicable regulatory
agencies. Failure to comply with any of these laws or regulations, the results
of increased regulatory audits and adjustments, or changes in the interpretation
of the coding of services or the amounts payable for services under these
programs could have a material adverse effect on our financial position and
results of operations.
15
The impact of legislative changes on our results of operations will depend
upon several factors, including the mix of inpatient and outpatient pathology
services, the amount of Medicare business, and changes in reimbursement levels
which are published in November of each year. Management continuously monitors
changes in legislation impacting reimbursement.
In prior years, we have been able to mitigate the impact of reductions in
Medicare reimbursement rates for anatomic pathology services through the
achievement of economies of scale and production efficiencies. Despite any
offsets, the recent substantial modifications to the physician fee schedule,
along with additional adjustments by Medicare, could have a material adverse
effect on average unit reimbursement in the future. In addition, other
third-party payors could adjust their reimbursement based on changes to the
Medicare fee schedule. Any reductions made by other payors could also have a
material negative impact on average unit reimbursement.
NET MANAGEMENT SERVICE REVENUE
Net management service revenue is based on a predetermined percentage of
operating income of the managed operations, before physician group retainage,
plus reimbursement of certain practice expenses as defined in each management
service agreement. Management fees are recognized at the time the net physician
group revenue is recorded by the physician group.
Generally, net management service revenue equates to net physician group
revenue less amounts retained by the physician groups, which we refer to as
physician group retainage. Net physician group revenue is equal to billed
charges reduced by provisions for bad debt and contractual adjustments.
Contractual adjustments represent the difference between amounts billed and
amounts reimbursable by commercial insurers and other third-party payors
pursuant to their respective contracts with the physician group. The provision
for bad debts represents an estimate of potential credit issues associated with
amounts due from patients, commercial insurers, and other third-party payors.
Net physician group revenue, which underlies our management service revenue, is
subject to the same legislative and regulatory factors discussed above with
respect to net patient revenue.
MEDICARE REIMBURSEMENT
Since 1992 the Centers for Medicare and Medicaid Services ("CMS") (formerly
known as the Health Care Financing Administration, or "HCFA") had paid for
physician's services under section 1848 of the Social Security Act. CMS
calculates and reimburses fees for all physician services ("Part B" fees),
including anatomic pathology services, based on a fee schedule methodology known
as the resource-based relative value system ("RBRVS").
The Medicare Part B fee schedule payment for each service is determined by
multiplying the total RVUs established for the service by a Geographic Practice
Cost Index ("GPCI"). The sum of this value is multiplied by a statutory
conversion factor. The number of RVUs assigned to each service is in turn
calculated by adding three separate components: work RVU (intensity of work),
practice exposure RVU (expense related to performing the service) and
malpractice RVU (malpractice costs associated with the service).
CMS reviews annually the RBRVS payment schedule in conjunction with its
budgeting process. The resulting payment schedule is published each year in the
Federal Register in November. The blended payment rates for services provided by
AmeriPath to Medicare patients, based on our values and locations of services,
increased by approximately 11.3% from 1999 to 2000, and by 6.8% from 2000 to
2001. A final rule published in the Federal Register on November 1, 2001
indicates that the conversion factor used in the Medicare Physician Fee Schedule
for 2002 was reduced by 5.4%. The RVUs were also changed in 2002, with certain
services getting an increase in RVUs, while others are decreased. We estimate
the overall impact to be neutral for 2002. As discussed in Recent Developments,
the proposed rules for 2003 would result in a 10% reduction in Medicare payment
rates and an overall 2% reduction in our net revenue. There can be no assurance
that we will receive similar increases or decreases in the future.
16
In 1999, CMS announced that it would cease the direct payment by Medicare
for the technical component of inpatient physician pathology services to an
outside independent laboratory because they concluded payment for the technical
component is included already in the payment to hospitals under the hospital
inpatient prospective payment system. Implementation of this change commenced
January 1, 2001. Under these rules, independent pathology laboratories would be
required to bill the hospital directly for technical services on hospital
Medicare inpatients. Congress, however, "grandfathered," for a period of two
years, certain existing hospital-lab arrangements in effect before July 22,
1999. Effective January 2001, hospital arrangements that were not grandfathered
are not reimbursed by Medicare for the technical component. The majority of our
hospital arrangements were grandfathered under the proposed rules. Upon
expiration of the two years, the grandfather provision is scheduled to expire.
Currently, there is proposed legislation which would extend the grandfather
provision for an additional year. We estimate that 1% to 2% of our total revenue
may be subject to these rules when the grandfather provision expires. When the
grandfather provision expires, we believe we will either negotiate acceptable
payment terms for these services from our hospitals or consider discontinuing
our technical component services resulting in lower costs.
MANAGED CARE CONTRACTING
The Company signed 12 new managed care agreements in the second quarter of
2002, primarily in the midwest, southeast, northeast and southwest regions,
generally on a non-exclusive fee-for-service basis, covering approximately 1.6
million lives.
CRITICAL ACCOUNTING POLICIES AND METHODS
Intangible Assets
As of June 30, 2002, we had net identifiable intangible assets and goodwill
of $254.1 million and $250.1 million, respectively. Management assesses on an
ongoing basis if there has been an impairment in the carrying value of its
intangible assets. If the undiscounted future cash flows over the remaining
amortization period of the respective intangible asset indicates that the value
assigned to the intangible asset may not be recoverable, the carrying value of
the respective intangible asset will be reduced. The amount of any such
impairment would be determined by comparing anticipated discounted future cash
flows from acquired businesses with the carrying value of the related assets. In
performing this analysis, management considers such factors as current results,
trends and future prospects, in addition to other relevant factors. Significant
changes in our future cash flow resulting from events such as loss of hospital
or national lab contracts, physician referrals, or management service agreements
could result in further charge offs of intangible assets.
Identifiable intangible assets include hospital contracts, physician
referral lists, laboratory contracts, and management service contracts acquired
in connection with acquisitions. Such assets are recorded at fair value the date
of acquisition as determined by management and are being amortized over the
estimated periods to be benefited, ranging from 10 to 40 years. In determining
these lives, we considered each practice's operating history, contract renewals,
stability of physician referral lists and industry statistics. If circumstances
change, indicating a shorter estimated period of benefit, future amortization
expense could increase.
Upon the adoption of FASB Statement No. 142 on January 1, 2002, we ceased
amortizing goodwill and performed an annual impairment analysis to assess the
recoverability of the goodwill, in accordance with the provisions of FASB
Statement No. 142. The results of the analysis indicated no impairment of
goodwill or other indefinite lived intangible assets. If we are required to
record an impaiarment charge in the future, it would have an adverse impact on
our results of operations.
Revenue Recognition
We recognize net patient service revenue at the time services are
performed. Unbilled receivables are recorded for services rendered during, but
billed subsequent to, the reporting period. Net patient service revenue is
reported at the estimated realizable amounts from patients, third-party payors
and others for services rendered. Revenue under
17
certain third-party payor agreements is subject to audit and retroactive
adjustments. Provision for estimated third-party payor settlements and
adjustments are estimated in the period the related services are rendered and
adjusted in future periods as final settlements are determined. The provision
and the related allowance are adjusted periodically, based upon an evaluation of
historical collection experience with specific payors for particular services,
anticipated collection levels with specific payors for new services, industry
reimbursement trends, and other relevant factors. Changes in these factors in
future periods could result in increases or decreases in the provision, our
results of operations and financial position.
Contingent Purchase Price
Our acquisitions, except for the pooling with Inform DX, have been
accounted for using the purchase method of accounting. The aggregate
consideration paid, and to be paid, is based on a number of factors, including
the acquired operation's demographics, size, local prominence, position in the
marketplace and historical cash flows from operations. Assessment of these and
other factors, including uncertainties regarding the health care environment,
often result in the sellers and us being unable to reach agreement on the final
purchase price. Therefore, we typically agree to pay a minimum purchase price
and to pay additional purchase price consideration to the sellers in proportion
to their respective ownership interest. The additional payments are contingent
upon the achievement of stipulated levels of operating earnings (as defined) by
each of the operations over periods typically ranging from three to five years
from the date of the acquisition as set forth in the respective agreements, and
are not contingent on the continued employment of the sellers. In certain cases,
the payments are contingent upon other factors such as the retention of certain
hospital contracts for periods ranging from three to five years. The amount of
the payments cannot be determined until the achievement of the operating
earnings levels or other factors during the terms of the respective agreements.
Additional payments made in connection with contingent notes are accounted for
as additional purchase price, which increases the recorded goodwill and, in
accordance with accounting principles, generally accepted in the United States
of America, are not reflected in our results of operations.
Provision for Doubtful Accounts
The provision for doubtful accounts is estimated in the period the related
services are rendered and adjusted in future accounting periods as necessary.
The estimates for the provision and the related allowance are based on an
evaluation of historical collection experience, the aging profile of the
accounts receivable, the historical doubtful account write-off percentages,
revenue channel (i.e., inpatient vs. outpatient) and other relevant factors.
Changes in these factors in future periods could result in increases or
decreases in the provision, our results of operations and financial position.
Principles of Consolidation
Our consolidated financial statements include the accounts of AmeriPath,
Inc., its wholly-owned subsidiaries, and companies in which we have the
controlling financial interest by means other than the direct record ownership
of voting stock. Intercompany accounts and transactions have been eliminated. If
it was determined that we do not have a controlling financial interest for any
or all companies where we do not have a direct ownership of voting stock, our
results of operations could be materially affected. We do not consolidate the
physician groups we manage as we do not have controlling financial interests in
those groups as described in EITF 97-2.
RESULTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2002 AND 2001
Changes in the results of operations between the three and six month
periods ended June 30, 2002 and 2001 are due primarily to the various
acquisitions we consummated subsequent to June 30, 2001. Reference to same store
means practices at which we provided services for the entire period for which
the amount is calculated and the entire prior comparable period, including de
novo (start-up) operations and expanded ancillary testing services added to
existing operations. During the second quarter of 2002, we completed one
acquisition.
PERCENTAGE OF NET REVENUE
18
The following table sets forth, for the periods indicated, certain
consolidated financial data as a percentage of net revenue (billings net of
contractual and other allowances):
Three Months Ended Six Months Ended
June 30, June 30,
---------------------- ----------------------
2002 2001 2002 2001
-------- -------- ------- --------
NET REVENUES 100.0% 100.0% 100.0% 100.0%
-------- -------- ------- --------
OPERATING COSTS AND EXPENSES:
Cost of services 48.8% 47.0% 48.5% 48.0%
Selling, general and administrative expenses 17.1% 17.3% 17.4% 17.4%
Provision for doubtful accounts 12.0% 11.9% 12.0% 11.4%
Amortization expense 2.2% 4.5% 2.4% 4.5%
Merger-related charges - -- -- 3.4%
-------- -------- ------- --------
Total operating costs and expenses 80.1% 80.7% 80.3% 84.7%
-------- -------- ------- --------
INCOME FROM OPERATIONS 19.9% 19.3% 19.7% 15.3%
Interest expense and other income, net .9% 4.3% .9% 4.6%
-------- -------- ------- --------
INCOME BEFORE INCOME TAXES 19.0% 15.0% 18.8% 10.7%
PROVISION FOR INCOME TAXES 7.6% 6.3% 7.5% 4.6%
-------- -------- ------- --------
NET INCOME 11.4% 8.7% 11.3% 6.1%
======== ======== ======= ========
Net Revenues
Net revenues increased by $15.6 million, or 14.9%, from $105.1 million for
the three months ended June 30, 2001 to $120.7 million for the three months
ended June 30, 2002. Same store net revenue increased $9.8 million or
19
9.3% from $105.1 million for the three months ended June 30, 2001 to $114.9
million for the three months ended June 30, 2002. We estimate that 3% of the
same store revenue increase was attributable to price and the remaining 6% of
the same store revenue increase was attributable to volume and mix. Same store
outpatient revenue increased $6.1 million, or 12.6%, same store hospital revenue
increased $3.3 million, or 6.7%, and same store management service revenue
increased $.4 million, or 5.2%, compared to the same period of the prior year.
The remaining increase in revenue of $5.8 million resulted from acquired
operations. Our mix of revenue for the second quarter of 2002 was 49.9%
outpatient, 44.7% inpatient (hospital based) and 5.4% management services.
During the three months ended June 30, 2002, approximately $7.6 million, or
6.3%, of the Company's net revenue was attributable to contracts with national
labs including Quest Diagnostics ("Quest") and Laboratory Corporation of America
Holdings ("LabCorp"). As previously discussed in Recent Developments, we are
currently experiencing substantial declines in volume from Quest work in our
Philadelphia and Southern California laboratories. As a result, we are
attempting to broaden our customer base in these markets to lessen any potential
impact. There can be no assurances that we will be able to recover lost volume.
Our decision or decisions by Quest or LabCorp to discontinue processing work
from the national laboratories, could materially harm our financial position and
results of operations, including the potential impairment of intangible assets.
As of June 30, 2002, we had net identifiable intangible assets related to lab
contracts of $2.7 million.
Net revenues increased by $29.8 million, or 14.6%, from $203.8 million for
the six months ended June 30, 2001 to $233.6 million for the six months ended
June 30, 2002. Same store net revenue increased $21.4 million, or 10.5%, from
$203.8 million for the six months ended June 30, 2001 to $225.2 million for the
six months ended June 30, 2002. Same store outpatient revenue increased $13.5
million, or 14.8%, same store hospital revenue increased $6.4 million, or 6.6%,
and same store management service revenue increased $1.4 million, or 9.7%,
compared to the same period of the prior year. The remaining increase in revenue
of $8.4 million resulted from the operations of laboratories acquired since June
2001.
In addition, approximately $25.0 million, or 10.7%, of the Company's net
revenue is derived from 29 hospitals operated by HCA, Inc. ("HCA"), formerly
known as Columbia/HCA Healthcare Corporation. Generally, any contracts or
relationships we may have with these and other hospitals are short-term and
allow for termination by either party with relatively short notice. HCA has been
under government investigation for some time, and we believe that HCA is
evaluating its operating strategies, including the possible sale, spin-off or
closure of certain hospitals. Closures or sales of HCA hospitals or terminations
or non-renewals of one or more of our contracts or relationships with HCA
hospitals could have a material adverse effect on our financial position and
results of operations.
Cost of Services
Cost of services consists principally of the compensation and fringe
benefits of pathologists, licensed technicians and support personnel, laboratory
supplies, shipping and distribution costs and facility costs. Cost of services
increased by $9.5 million, or 19.2%, from $49.4 million for the three months
ended June 30, 2001 to $58.9 million for the same period in 2002. The increase
in cost of services relates primarily to the increase in net revenues
(approximately $6.7 million) and the practices acquired since June 30, 2001
(approximately $2.8 million). The increase can also be attributed to the
increase in physician compensation. Cost of services, as a percentage of net
revenues, increased slightly from 47.0% for the three months ended June 30, 2001
to 48.8% in the comparable period of 2002. Gross margin decreased from 53.0% for
the three months ended June 30, 2001 to 51.2% for the same period in 2002. The
decline in the gross margin is attributable to a reduction in Quest business at
our Philadelphia and Southern California laboratories. The Company elected to
maintain staff in anticipation of replacing that business with retail work.
These excess staff positions cost 1% of gross margin.
Cost of services increased by $15.4 million, or 15.7%, from $97.8 million
for the six months ended June 30, 2001 to $113.2 million for the same period in
2002. The increase in cost of services can be attributed primarily to the
increase in net revenues (approximately $12.1 million) and the practices
acquired since June 30, 2001 (approximately $3.2 million). Cost of services, as
a percentage of net revenues, increased slightly from 48.0% for
20
the six months ended June 30, 2001 to 48.5% in the comparable period of 2002.
Gross margin decreased from 52.0% in the six months ended June 30, 2001 to 51.6%
for the same period in 2002.
Selling, General and Administrative Expenses
The cost of corporate support, sales and marketing, and billing and
collections comprise the majority of what is classified as selling, general and
administrative expenses. As a percentage of consolidated net revenues, selling,
general and administrative expenses decreased from 17.3% for the three months
ended June 30, 2001 to 17.1% for the same period of 2002, as the Company
continues to implement measures to better control these costs and continues to
spread these costs over a larger revenue base. One of the Company's objectives
is to decrease these costs as a percentage of net revenues; however, these
costs, as a percentage of net revenue, may increase as the Company continues to
invest in marketing, information systems and billing operations.
Selling, general and administrative expenses increased by $2.5 million, or
13.6%, from $18.2 million for the three months ended June 30, 2001 to $20.6
million for the comparable period of 2002. Of this increase, approximately $.7
million was attributable to the increase in billing and collection costs, $.6
million in increased IT costs to enhance the Company's information and support
services, and approximately $.4 million is attributable to the acquisitions the
Company completed after June 30, 2001. The remaining increase of $.8 million was
due primarily to increased staffing levels in marketing, human resources and
accounting, salary increases during the fourth quarter of 2001, and costs
incurred to expand the Company's administrative support infrastructure. The
increase in marketing costs includes the cost of additional marketing personnel
to cover new markets for dermatopathology, marketing literature, and products to
expand the Company's penetration in the urology, gastroenterology and oncology
markets.
As a percentage of consolidated net revenues, selling, general and
administrative expenses remained constant at 17.4% for the six months ended June
30, 2001 when compared to the same period of 2002. Selling, general and
administrative expenses increased by $5.3 million, or 15.0%, from $35.4 million
for the six months ended June 30, 2001 to $40.7 million for the comparable
period of 2002. The increase can be attributed to the same reasons stated above,
including approximately $1.6 million attributable to the increase in billing and
collection costs, $2.5 million in increased sales, marketing and IT costs, and
approximately $.5 million attributable to the acquisitions the Company completed
after June 30, 2001.
Provision for Doubtful Accounts
The provision for doubtful accounts increased by $1.9 million, or 15.1%,
from $12.5 million for the three months ended June 30, 2001 to $14.4 million for
the same period in 2002. The provision for doubtful accounts as a percentage of
net revenues was 11.9% and 12.0% for the three month periods ended June 30, 2001
and 2002, respectively.
The provision for doubtful accounts increased by $4.9 million, or 21.1%,
from $23.2 million for the six months ended June 30, 2001 to $28.1 million for
the same period in 2002. The provision for doubtful accounts as a percentage off
net revenues was 11.4% and 12.0% for the six month periods ended June 30, 2001
and 2002, respectively. This increase was related primarily to conservative
reserve practices as same store revenue accelerates, extended account aging in
some practices where billing systems have been converted and increased clinical
professional component billing, which generally has a higher bad debt ratio.
Amortization Expense
Amortization expense decreased by $1.9 million, or 39.8%, from $4.7 million
for the three months ended June 30, 2001 to $2.8 million for the same period of
2002. The decrease is attributable to the discontinuance of goodwill
amortization as promulgated by Statement of Financial Accounting Standards No.
142, "Goodwill and Other
21
Intangible Assets", which was effective January 1, 2002. Identifiable intangible
amortization expense is expected to increase in the future as a result of
additional identifiable intangible assets arising from future acquisitions.
Amortization expense decreased by $3.6 million, or 39.2%, from $9.2 million
for the six months ended June 30, 2001 to $5.6 million for the same period of
2002.
We continually evaluate whether events or circumstances have occurred that
may warrant revisions to the carrying values of our goodwill and other
identifiable intangible assets, or to the estimated useful lives assigned to
such assets. Any significant impairment recorded on the carrying values of our
goodwill or other identifiable intangible assets could materially harm results
of operations. Such impairment would be recorded as a charge to operating profit
and reduction in intangible assets.
Merger-related Charges
The merger-related charges of $7.1 million for the six months ended June
30, 2001 relate to AmeriPath's acquisition of Inform DX and include transaction
costs and costs related to the closing of the Inform DX corporate office in
Nashville and the consolidation or closing of the overlapping operations of
Inform DX in New York and Pennsylvania.
Income from Operations
Income from operations increased $3.7 million, or 18.1%, from $20.3 million
for the three months ended June 30, 2001 to $24.0 million in the same period of
2002.
Income from operations increased $14.9 million, or 48.0%, from $31.1
million for the six months ended June 30, 2001 to $46.0 million in the same
period of 2002. Without giving effect to merger-related charges of $7.1 million
in 2001, income from operations increased by $7.8 million, or 20.5%, from $38.2
million in the six months ended June 30, 2001 to $46.0 million in the same
period of 2002.
Interest Expense
Interest expense decreased by $3.6 million, or 77.0%, from $4.7 million for
the three months ended June 30, 2001 to $1.1 million for the same period in
2002. This decrease was attributable to a combination of lower average amount of
debt outstanding and lower interest rates during the three months ended June 30,
2002. For the three months ended June 30, 2002, average indebtedness outstanding
was $103.4 million, compared to average indebtedness of $211.9 million
outstanding in the same period of 2001. The Company's effective interest rate
was 4.2% and 8.9% for the three month periods ended June 30, 2002 and 2001,
respectively.
Interest expense decreased by $7.3 million, or 77.4% from $9.4 million for
the six months ended June 30, 2002 to $2.1 million for the same period in 2002.
This decrease was attributable to a combination of lower average amount of debt
outstanding and lower interest rates during the six months ended June 30, 2002.
The decrease in the average indebtedness was due to the Company completing a
secondary offering and using the proceeds to repay debt in the fourth quarter of
2001. In addition, during the fourth quarter of 2001, the Company entered into a
new credit facility agreement. The new credit facility has a borrowing rate
based on the Company's leverage ratio. As of June 30, 2002, the borrowing rate
was LIBOR plus 150 basis points.
Provision for Income Taxes
22
The effective income tax rate was approximately 41.8% and 40.0% for the
three-month period ended June 30, 2001 and 2002, respectively. In 2001, the
effective tax rate was higher than AmeriPath's statutory rates primarily due to
the non-deductibility of the goodwill amortization related to the Company's
acquisitions.
The effective income tax rate was approximately 43.2% and 40.0% for the
six-month periods ended June 30, 2001 and 2002, respectively. In addition to
non-deductible goodwill amortization, the Company had non-deductible
merger-related charges for the six-month period ended June 30, 2001, which
further increased the effective tax rate. The effective tax rate for the six
month period ended June 30, 2001 excluding these items would have been
approximately 41.7%.
Net Income
Net income for the three months ended June 30, 2002 was $13.8 million, an
increase of $4.6 million, or 50.5%, over the same period in 2001. Diluted
earnings per share for the three months ended June 30, 2002 increased to $0.44
from $0.35 for the comparable period of 2001, based on 31.2 million and 26.1
million weighted average shares outstanding, respectively.
Net income for the six months ended June 30, 2002 was $26.4 million, an increase
of $14.0 million, or 113.2%, over the same period in 2001. Without giving effect
to the merger-related charges of $7.1 million in 2001, net income increased by
$9.5 million, or 56.6%, from $16.9 million in the six months ended June 30, 2001
to $26.4 million in the same period of 2002. Diluted earnings per share for the
six months ended June 30, 2002 increased to $0.85 from $0.48 for the comparable
period of 2001, based on 26.1 million and 31.2 million weighted average shares
outstanding, respectively. Diluted earnings per share was $0.65 for the six
months ended June 30, 2001, without giving effect to any special charges.
LIQUIDITY AND CAPITAL RESOURCES
At June 30, 2002, the Company had working capital of approximately $64.0
million, an increase of $7.2 million from the working capital of $56.8 million
at December 31, 2001. The increase in working capital was due primarily to the
increase in net accounts receivable of $7.4 million and a decrease in accounts
payable and accrued expenses of $3.4 million, partially offset by a reduction in
cash and cash equivalents of $3.0 million.
For the six month periods ended June 30, 2001 and 2002, cash flows from
operations were $15.8 million, 7.7% of net revenue, and $26.2 million, 11.2% of
net revenue, respectively. Excluding pooling merger-related charges paid for
Inform DX of $3.1 million, cash flow from operations would have been $18.9
million, or 9.3% of net revenue for the six months ended June 30, 2001. For the
six months ended June 30, 2002, cash flow from operations and borrowings under
the Company's credit facility were used to make contingent note payments of
$27.4 million, fund acquisitions of $9.3 million, and acquire $3.8 million of
property and equipment.
The credit facility provides for borrowings of up to $200 million, with
commitments totaling $175 million, in the form of a revolving loan that may be
used for working capital purposes and to fund acquisitions. As of June 30, 2002,
$98.6 million was outstanding under the revolving loan with an annual effective
interest rate of 4.2%. In addition, the Company has $1.9 million in letters of
credit outstanding as of June 30, 2002. At June 30, 2002, the Company had $74.5
million available under its credit facility.
The credit facility has a five-year term with a final maturity date of
November 30, 2006. Interest is payable monthly at variable rates which are
based, at the Company's option, on the agent's base rate (4.75% at June 30,
2002) or the LIBOR rate plus a premium that is based on the Company's ratio of
total funded debt to pro forma consolidated earnings before interest, taxes,
depreciation and amortization. As of June 30, 2002, the LIBOR premium was 150
basis points. The new facility also requires a commitment fee to be paid
quarterly equal to 0.375% of the unused portion of the total commitment. The
credit facility has three basic financial covenants regarding leverage, fixed
charge coverage and interest coverage. In addition, the agreement has a number
of nonfinancial covenants. At June 30, 2002, we are in compliance with the
covenants of the credit facility. The unused commitments under the credit
facility will be used for general working capital needs and our acquisition
program.
23
During the second quarter of 2002, the Company completed one acquisition.
Total consideration paid consisted of cash, common stock and consideration in
the form of contingent notes and the assumption of certain liabilities.
In connection with all of our acquisitions, we generally agree to pay a
base purchase price plus additional contingent purchase price consideration to
the sellers of the practices. The additional payments are generally contingent
upon the achievement of stipulated levels of operating earnings by the acquired
practices over periods typically ranging from three to five years from the date
of the acquisition, and are not contingent on the continued employment of the
sellers of the practices. In certain cases, the payments are contingent upon
other factors such as the retention of certain hospital contracts or
relationships for periods ranging from three to five years. The amount of the
payments cannot be determined until the achievement of the operating earnings
levels or other factors during the terms of the respective agreements. If the
maximum specified levels of operating earnings for each acquired practice are
achieved, we would make aggregate maximum payments, including principal and
interest, of approximately $142.4 million over the next three to five years. A
lesser amount or no payments at all would be made if the stipulated levels of
operating earnings specified in each agreement were not met. In the second
quarter of 2002, we made contingent note payments aggregating $9.8 million.
These contingent note payments are currently estimated to be $8.6 million and
$34-$35 million for the remainder of 2002 and the year 2003, respectively. After
2003, without giving effect to future acquisitions, these payments are projected
to decline. However, future acquisitions are likely and, therefore, depending
upon the timing and amount of such acquisitions, aggregate contingent note
payments could increase.
We expect to continue to use our credit facility to fund acquisitions and
for working capital. We anticipate that funds generated by operations and funds
available under our credit facility will be sufficient to meet working capital
requirements and anticipated contingent note obligations, and to finance capital
expenditures over the next 12 months. Further, in the event additional payments
under the contingent notes issued in connection with acquisitions become due, we
believe that the incremental cash generated from operations would exceed the
cash required to satisfy our payment, if any, of the contingent obligations in
any one-year period. Such payments, if any, will result in a corresponding
increase in goodwill. Funds generated from operations and funds available under
the credit facility may not be sufficient to implement our longer-term growth
strategy. We may be required to seek additional financing through additional
increases in the credit facility, to negotiate credit facilities with other
banks or institutions or to seek additional capital through private placements
or public offerings of equity or debt securities. No assurances can be given
that we will be able to extend or increase the existing credit facility, secure
additional bank borrowings or complete additional debt or equity financings on
terms favorable to us or at all.
24
QUALIFICATION OF FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Statements contained anywhere in this Form 10-Q that are not
limited to historical information are considered forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934, including, without limitation,
statements regarding the Company's expectations, beliefs, intentions, plans or
strategies regarding the future. These forward-looking statements are based
largely on the Company's expectations which are subject to a number of known and
unknown risks, uncertainties and other factors discussed in this report and in
other documents filed by the Company with the Securities and Exchange
Commission, which may cause actual results to be materially different from those
anticipated, expressed or implied by the forward-looking statements. All
forward-looking statements included in this document are based on information
available to the Company on the date hereof, and the Company assumes no
obligation to update any such forward-looking statements to reflect future
events or circumstances. Forward-looking statements are sometimes indicated by
words such as "may," "should," "believe," "expect," "anticipate" and similar
expressions.
In addition to the risks and uncertainties identified elsewhere herein and
in other documents filed by the Company with the Securities and Exchange
Commission, the following factors should be carefully considered when evaluating
the Company's business and future prospects: general economic conditions;
competition and changes in competitive factors; the extent of success of the
Company's operating initiatives and growth strategies (including without
limitation, the Company's continuing efforts to (i) achieve continuing
improvements in performance of its current operations, by reason of various
synergies, marketing efforts, revenue growth, cost savings or otherwise, (ii)
transition into becoming a fully integrated healthcare diagnostic information
provider, including the Company's efforts to develop, and the Company's
investment in, new products, services, technologies and related alliances, such
as the alliance with Genomics Collaborative, Inc. (iii) acquire or develop
additional pathology practices (as further described below), and (iv) develop
and expand its managed care contracts); federal and state healthcare regulation
(and compliance); reimbursement rates under government-sponsored and third party
healthcare programs and the payments received under such programs; changes in
coding; changes in technology; dependence upon pathologists and contracts; the
ability to attract, motivate, and retain pathologists; labor and technology
costs; marketing and promotional efforts; the availability of pathology
practices in appropriate locations that the Company is able to acquire on
suitable terms or develop; the successful completion and integration of
acquisitions (and achievement of planned or expected synergies); access to
sufficient amounts of capital on satisfactory terms; and tax laws. In addition,
the Company's strategy to penetrate and develop new markets involves a number of
risks and challenges and there can be no assurance that the healthcare
regulations of the new states in which the Company enters and other factors will
not have a material adverse effect on the Company. The factors which may
influence the Company's success in each targeted market in connection with this
strategy include: the selection of appropriate qualified practices; negotiation,
execution and consummation of definitive acquisition, affiliation, management
and/or employment agreements; the economic stability of each targeted market;
compliance with state, local and federal healthcare and/or other laws and
regulations in each targeted market (including health, safety, waste disposal
and zoning laws); compliance with applicable licensing approval procedures;
restrictions under labor and employment laws, especially non-competition
covenants. Past performance is not necessarily indicative of future results.
Certain risks, uncertainties and other factors discussed or noted above are more
fully described elsewhere in this Report, including under the caption--"Risk
Factors" below.
25
RISK FACTORS
You should carefully consider each of the following risks and all of the
other information set forth in this Form 10-Q. The risks and uncertainties
described below are not the only ones we face. Additional risks and
uncertainties not presently known to us or that we currently believe to be
immaterial may also adversely affect our business.
If any of the following risks actually occur, our business prospects,
financial condition and results of operations could be materially adversely
affected and the trading price of our common stock could decline. In any such
case, you could lose all or part of your investment in our company.
Our business could be materially harmed by future interpretation or
implementation of state laws regarding prohibitions on the corporate practice of
medicine.
We acquire or affiliate with pathology operations located in many states
across the country. However, the laws of many states prohibit business
corporations, including AmeriPath and its subsidiaries, from owning corporations
that employ physicians, or from exercising control over the medical judgments or
decisions of physicians. These laws and their interpretations vary from state to
state and are enforced by both the courts and regulatory authorities, each with
broad discretion. The manner in which we operate each organization is determined
primarily by the corporate practice of medicine restrictions of the state in
which the organization is located and other applicable regulations.
We believe that we are currently in material compliance with the corporate
practice of medicine laws in each of the states in which we operate.
Nevertheless, it is possible that regulatory authorities or other parties may
assert that we are engaged in the unauthorized corporate practice of medicine.
If such a claim were successfully asserted in any jurisdiction, we could be
subject to civil and criminal penalties, which could exclude us from
participating in Medicare, Medicaid and other governmental health care programs,
or we could be required to restructure our contractual and other arrangements.
Any restructuring of our contractual and other arrangements with our operations
could result in lower revenues, increased expenses and reduced influence over
the business decisions of those operations. Alternatively, some of our existing
contracts could be found to be illegal and unenforceable, which could result in
the termination of those contracts and an associated loss of revenue. In
addition, expansion of our operations to other corporate practice states may
require structural and organizational modification to the form of relationships
that we currently have with our operations and hospitals. Such modifications
could result in less profitable operations, less influence over the business
decisions and failure to achieve our growth objectives.
We could be hurt by future interpretation or implementation of federal and state
anti-kickback laws.
Federal anti-kickback laws and regulations prohibit the offer, payment,
solicitation and receipt of any form of remuneration in exchange for referrals
of products or services for which payment may be made by Medicare, Medicaid or
other federal health care programs. Violations of federal anti-kickback laws are
punishable by monetary fines, civil and criminal penalties and exclusion from
participation in Medicare, Medicaid and other governmental health care programs.
Several states have similar laws. While we believe our operations are in
material compliance with applicable Medicare and fraud and abuse laws, including
the anti-kickback law, there is a risk that government authorities might take a
contrary position or might investigate our arrangements with physicians and
third parties, particularly those arrangements that do not satisfy the
compliance safe harbors provided under the relevant regulations or that are
similar to arrangements found to be problematic in advisory opinions of the
Department of Health and Human Services Office of Inspector General (OIG). For
example, the OIG has addressed physician practice management arrangements in an
advisory opinion and found that management fees based on a percentage of
practice revenues may violate the federal anti-kickback statute. While we
believe our fee arrangements can be distinguished from those addressed in the
opinion, government authorities may disagree. Such occurrences, regardless of
their outcome, could damage our reputation and adversely affect important
business relationships that we have with third parties, including physicians,
hospitals and private payors. If our arrangements with physicians and third
parties were found to be illegal, we could be subject to civil and criminal
penalties, including fines and possible exclusion from participation in
government payor programs. Significant fines could cause liquidity
26
problems and adversely affect our results of operations. Exclusion from
participation in government payor programs, which represented 21% of our
collections from owned operations during the six months ended June 30, 2002,
would eliminate an important source of revenue and could materially adversely
affect our business. In addition, some of our existing contracts could be found
to be illegal and unenforceable, which could result in the termination of those
contracts and an associated loss of revenue.
Our business could be harmed by future interpretation or implementation of the
federal Stark Law and other state and federal anti-referral laws.
We are also subject to federal and state statutes and regulations banning
payments for referrals of patients and referrals by physicians to health care
providers with whom the physicians have a financial relationship. The federal
Stark Law applies to Medicare and Medicaid and prohibits a physician from
referring patients for certain services, including laboratory services, to an
entity with which the physician has a financial relationship. Financial
relationship includes both investment interests in an entity and compensation
arrangements with an entity. The state laws and regulations vary significantly
from state to state, are often vague and, in many cases, have not been
interpreted by courts or regulatory agencies. These state laws and regulations
generally apply to services reimbursed by both governmental and private payors.
Violations of these federal and state laws and regulations may result in
prohibition of payment for services rendered, loss of licenses, fines, criminal
penalties and exclusion from governmental and private payor programs. We have
financial relationships with our pathologists, as defined by the federal Stark
Law, in the form of compensation arrangements, ownership of our common stock and
contingent promissory notes issued by us in connection with acquisitions. While
we believe that our financial relationships with pathologists and referral
practices are in material compliance with applicable laws and regulations,
government authorities might take a contrary position or prohibited referrals
may occur. We cannot be certain that pathologists who own our capital stock or
hold contingent promissory notes will not violate these laws or that we will
have knowledge of the identity of all beneficial owners of our capital stock. If
our financial relationships with pathologists were found to be illegal, or if
prohibited referrals were found to have been made, we could be subject to civil
and criminal penalties, including fines, exclusion from participation in
government and private payor programs and requirements to refund amounts
previously received from government and private payors. In addition, expansion
of our operations to new jurisdictions, or new interpretations of laws in our
existing jurisdictions, could require structural and organizational
modifications of our relationships with physicians to comply with that
jurisdiction's laws. Such structural and organizational modifications could
result in lower profitability and failure to achieve our growth objectives.
Our business could be materially harmed by future interpretation or
implementation of state laws regarding prohibitions on fee-splitting.
Many states prohibit the splitting or sharing of fees between physicians
and non-physicians. These laws vary from state to state and are enforced by
courts and regulatory agencies, each with broad discretion. Some states have
interpreted management agreements between entities and physicians as unlawful
fee-splitting. We believe our arrangements with physicians comply in all
material respects with the fee-splitting laws of the states in which we operate.
Nevertheless, it is possible regulatory authorities or other parties could claim
we are engaged in fee-splitting. If such a claim were successfully asserted in
any jurisdiction, our pathologists could be subject to civil and criminal
penalties and we could be required to restructure our contractual and other
arrangements. Any restructuring of our contractual and other arrangements with
our operations could result in lower revenues, increased expenses in the
operations and reduced influence over the business decisions. Alternatively,
some of our existing contracts could be found to be illegal and unenforceable,
which could result in the termination of those contracts and an associated loss
of revenue. In addition, expansion of our operations to other states with
fee-splitting prohibitions may require structural and organizational
modification to the form of our current relationships. Any modifications could
result in less profitable relationships, less influence over the business
decisions of and failure to achieve our growth objectives.
We could be hurt by future interpretation or implementation of state and federal
anti-trust laws.
27
In connection with the corporate practice of medicine laws, the operations
with which we are affiliated in some states are organized as separate legal
entities. As such, the separate legal entities may be deemed to be persons
separate both from us and from each other under the antitrust laws and,
accordingly, subject to a wide range of laws that prohibit anti-competitive
conduct among separate legal entities. In addition, we are seeking to acquire or
affiliate with established and reputable pathology organizations in new
geographic markets. While we believe that we are in material compliance with
these laws and intend to comply with any laws that may apply to our development
of integrated health care delivery networks, courts or regulatory authorities
could nevertheless take a contrary position or investigate our business
practices. If our business practices were found to violate these laws, we could
be required to pay substantial fines, penalties and damage awards, or we could
be required to restructure our business in a manner that would materially reduce
our profitability or impede our growth.
Our business could be harmed by future interpretation or implementation of the
Health Care Insurance Portability and Accountability Act.
The Health Care Insurance Portability and Accountability Act, or HIPAA,
created provisions that impose criminal penalties for fraud against any health
care benefit program, for theft or embezzlement involving health care and for
false statements in connection with the payment of any health benefits. The
HIPAA provisions apply not only to federal programs, but also to private health
benefit programs. HIPAA also broadened the authority of the OIG to exclude
participants from federal health care programs. Because of the uncertainties as
to how the HIPAA provisions will be enforced, we are currently unable to predict
their ultimate impact on us. Compliance with HIPAA could cause us to modify our
business operations in a manner that would increase our operating costs or
impede our growth. In addition, although we are unaware of any current
violations of HIPAA, if we were found to be in violation of HIPAA, the
government could seek penalties against us or seek to exclude us from
participation in government payor programs. Significant fines could cause
liquidity problems and adversely affect our results of operations. Exclusion
from participation in government payor programs, which represented 21% of
collections for the first six months of 2002, would eliminate an important
source of revenue and could materially adversely affect our business.
Federal and state regulation of the privacy, security and transmission of health
information could restrict our operations, impede the implementation of our
business strategies or cause us to incur significant costs.
The privacy, security and transmission of health information is subject to
federal and state laws and regulations, including HIPAA. Some of our operations
will be subject to HIPAA and its regulations. Because HIPAA's privacy
regulations do not supersede state laws that are more stringent, we will have to
comply both with the federal privacy regulations under HIPAA and with any state
privacy laws that are more stringent than HIPAA. Our operations that are subject
to HIPAA must be in compliance with HIPAA's privacy regulations by April 2003.
Another set of regulations issued under HIPAA establishes uniform standards
relating to data reporting, formatting, and coding that covered entities must
use when conducting certain transactions involving health information. The
compliance date for these regulations is October 2002, although the
Administrative Simplification Compliance Act grants a covered entity an
additional one-year to achieve compliance if it files a compliance plan on or
before October 15, 2002. We plan to file such a compliance plan to extend the
applicable compliance date for these regulations. A third set of regulations,
which have not yet been finalized, will establish minimum security requirements
to protect health information that is stored or transmitted electronically. The
different sets of HIPAA regulations could result in significant financial
obligations for us and will pose increased regulatory risk. The privacy
regulations could limit our use and disclosure of patient health information and
could impede the implementation of some of our business strategies, such as our
genomics initiatives. For example, the Department of Health and Human Services,
or HHS, has indicated that cells and tissues are not protected health
information, but that analyses of them are protected. HHS has stated that if a
person provides cells to a researcher and tells the researcher that the cells
are an identified individual's cancer cells, that accompanying statement is
protected health information. At this time, we are unable to determine the full
impact of the HIPAA regulations on our business and our business strategies or
the total cost of complying with the regulations, but the impact and the cost
could be significant. Many states have enacted, or indicated an intention to
enact, privacy laws similar to HIPAA or that would be more stringent than HIPAA.
These state laws could also restrict our operations, impede the implementation
of our business strategies or cause us to incur significant compliance costs. In
addition, failure to comply with federal or state privacy laws and regulations
could subject us to civil or criminal penalties.
28
We charge our clients on a fee-for-service basis, so we incur financial risk
related to collections as well as potentially long collection cycles when
seeking reimbursement from third-party payors.
Substantially all of our net revenues are derived from our operations'
charging for services on a fee-for-service basis. Accordingly, we assume the
financial risk related to collection, including the potential uncollectability
of accounts, long collection cycles for accounts receivable and delays attendant
to reimbursement by third-party payors, such as governmental programs, private
insurance plans and managed care organizations. Our provision for doubtful
accounts for the six months ended June 30, 2002 was 12.0% of net revenues, with
net revenues from inpatient services having a provision for doubtful accounts of
approximately 20.5%. If our revenue from hospital-based services increases as a
percentage of our total net revenues, our provision for doubtful accounts as a
percentage of total net revenues may increase. Increases in write-offs of
doubtful accounts, delays in receiving payments or potential retroactive
adjustments and penalties resulting from audits by payors may adversely affect
our operating cash flow and liquidity, require us to borrow funds to meet our
current obligations, reduce our profitability, impede our growth or otherwise
materially adversely affect our business.
Significant collection risk exists for clinical professional component ("CPC")
charges for non-Medicare patients.
In addition to services billed on a fee-for-service basis, our
hospital-based pathologists generally have supervision and oversight
responsibility for their roles as Medical Directors of the hospitals' clinical,
microbiology and blood banking operations. In some instances, we bill
non-Medicare patients according to a fee schedule for what is referred to as CPC
charges. Our historical collection experience for CPC procedures is
significantly lower than other anatomic pathology procedures. For example, one
of our billing operations collects approximately 35% of net charges for hospital
CPC services compared to 70% for hospital anatomic pathology services. This
translates to a 50% bad debt rate for CPC charges and increases our overall bad
debt percentage. For Medicare patients, the pathologist is typically paid a
director's fee or a "Part A" fee by the hospital. Hospitals and third-party
payors are continuing to increase pressure to reduce our revenue from CPC and
"Part A" fees, and in the future we may sustain substantial decreases in this
revenue source or experience further deterioration in CPC collectibility. In the
event that hospitals and third party payors are successful in reducing these
sources of revenue, without corresponding price increases for other services,
our profits will be negatively impacted since the majority of the costs
supporting these revenues are fixed costs in the form of physicians expense.
We rely upon reimbursement from government programs for a significant portion of
our collections, and therefore our business would be harmed if reimbursement
rates from government programs decline.
We derived 21% of our collections in the first six months of 2002 from
payments made by government sponsored health care programs, principally Medicare
and Medicaid. These programs are subject to substantial regulation by federal
and state governments. Any changes in reimbursement regulations, policies,
practices, interpretations or statutes that place limitations on reimbursement
amounts or change reimbursement coding practices could materially harm our
business by reducing revenues and lowering profitability. Increasing budgetary
pressures at both the federal and state levels and concerns over escalating
costs of health care have led, and may continue to lead, to significant
reductions in health care reimbursements. State concerns over the growth in
Medicaid expenditures also could result in significant payment reductions. Since
these programs generally reimburse on a fee schedule basis, rather than a
charge-related basis, we generally cannot increase net revenue by increasing the
amount charged for services provided. As a result, cost increases may not be
able to be recovered from government payors. In addition, Medicare, Medicaid and
other government health care programs are increasingly shifting to forms of
managed care, which generally offer lower reimbursement rates. Some states have
enacted legislation to require that all Medicaid patients be transitioned to
managed care organizations, which could result in reduced payments to us for
such patients. Similar legislation may be enacted in other states. In addition,
a state-legislated shift of Medicaid patients to a managed care organization
could cause us to lose some or all Medicaid business in that state if we were
not selected by the managed care organization as a participating provider.
Additionally, funds received under all health care reimbursement programs are
subject to audit with respect to the proper billing for physician services and,
29
accordingly, repayments and retroactive adjustments of revenue from these
programs could occur. We expect that there will continue to be proposals to
reduce or limit Medicare and Medicaid reimbursements.
The continued growth of managed care may have a material adverse effect on our
business.
The number of individuals covered under managed care contracts or other
similar arrangements has grown over the past several years and may continue to
grow in the future and a substantial portion of our net revenue is from
reimbursement from managed care organizations. Entities providing managed care
coverage have been successful in reducing payments for medical services in
numerous ways, including entering into arrangements under which payments to a
service provider are capitated, limiting testing to specified procedures,
denying payment for services performed without prior authorization and refusing
to increase fees for specified services. These trends reduce revenues, increase
the cost of doing business and limit the ability to pass cost increases on to
customers. The continued growth of the managed care industry and increased
efforts to reduce payments to medical care providers could materially harm our
business.
There have been an increasing number of state and federal investigations of
hospitals and hospital laboratories, which may increase the likelihood of
investigations of our business practices.
Significant media and public attention has been focused on the health care
industry due to ongoing federal and state investigations reportedly related to
referral and billing practices, laboratory and home health care services and
physician ownership and joint ventures involving hospitals. Most notably,
HCA-The Healthcare Company, or HCA, is reportedly under investigation with
respect to such practices. We provide medical director services for numerous
hospital laboratories, including 29 HCA hospital laboratories as of June 30,
2002. Therefore, the government's ongoing investigation of HCA or other hospital
operators could result in governmental investigations of one or more of our
operations. In addition, the OIG and the Department of Justice have initiated
hospital laboratory billing review projects in certain states, including some in
which we operate, and are expected to extend such projects to additional states,
including states in which we operate. These projects further increase the
likelihood of governmental investigations of laboratories that we own or
operate. Although we monitor our billing practices and hospital arrangements for
compliance with prevailing industry practices under applicable laws, such laws
are complex and constantly evolving, and it is possible that governmental
investigators may take positions that are inconsistent with our practices or
industry practices. The government's investigations of entities with which we
contract may materially harm our business, including termination or amendment of
one or more of our contracts or the sale of hospitals, potentially disrupting
the performance of services under our contracts. In addition, some indemnity
insurers and other non-governmental payors have sought repayment from providers,
including laboratories, for alleged overpayments.
The heightened scrutiny of Medicare and Medicaid billing practices in recent
years may increase the possibility that we will become subject to costly and
time consuming lawsuits and investigations.
Payors periodically reevaluate the services for which they provide
reimbursement. In some cases, government payors such as Medicare also may seek
to recoup payments previously made for services determined not to be
reimbursable. Any such action by payors would adversely affect our revenues and
earnings. In addition, under the federal False Claims Act, any person convicted
of submitting false or fraudulent claims to the government may be required to
make significant payments, including damages and penalties in addition to
repayments of amounts not properly billed, and may be excluded from
participating in Medicare, Medicaid and other government health care programs.
Many states have similar false claims laws. The federal government has become
more aggressive in examining laboratory billing practices and seeking repayments
and penalties allegedly resulting from improper billing for services, such as
using an improper billing code for a test to realize higher reimbursement. While
the primary focus of this initiative has been on hospital laboratories and on
routine clinical chemistry tests, which comprise only a portion of our revenues,
the scope of this initiative could expand and it is not possible to predict
whether or in what direction the expansion might occur. In addition, recent
government enforcement efforts have asserted poor quality of care as the basis
for a false claims action. Private insurers may also bring actions under false
claims laws and, in some circumstances, private whistleblowers may bring false
claim suits on behalf of the
30
government. While we believe that our practices are proper and do not include
any allegedly improper practices now being examined, the government could take a
contrary position or could investigate our practices. Furthermore, HIPAA and the
joint federal and state anti-fraud initiative commenced in 1995 called Operation
Restore Trust have strengthened the powers of the OIG and increased funding for
Medicare and Medicaid audits and investigations. As a result, the OIG is
expanding the scope of its health care audits and investigations. Federal and
state audits and inspections, whether on a scheduled or unannounced basis, are
conducted from time to time at our facilities. If a negative finding is made as
a result of any such investigation, we could be required to change coding
practices, repay amounts paid for incorrect practices, pay substantial penalties
or cease participating in Medicare, Medicaid and other government health care
programs.
We have recently received subpoenas issued by the United States Attorney's
office in Tampa, Florida seeking information with respect to an investigation
relating to Medicare billing and possible financial inducements in connection
with a Florida physician who is not an AmeriPath pathologist but is a client of
AmeriPath. We are providing information to the United States Attorney's office
and intend to cooperate in the investigation. We also are conducting our own
internal investigation of the matter. It is not possible at this point in the
investigation to determine whether the government will pursue action against
AmeriPath or to assess the merits of possible defenses AmeriPath might have to
any such action. Accordingly, no assurances can be given regarding the ultimate
outcome of the investigation.
We derive a significant portion of our revenues from short-term hospital
contracts and hospital relationships that can easily be terminated.
Many of our hospital contracts provide that the hospital or we may
terminate the agreement prior to the expiration of the initial or any renewal
term with relatively short notice and without cause. We also have business
relationships with hospitals that are not subject to written contracts and that
may be terminated by the hospitals at any time. Loss of any particular hospital
contract or relationship would not only result in a loss of net revenue to us
under that contract or relationship, but may also result in a loss of outpatient
net revenue that may be derived from our association with the hospital and its
medical staff. Any such loss could also result in an impairment of the value of
the assets we have acquired or may acquire, requiring substantial charges to
earnings. For example, during the fourth quarter of 2000, we were unsuccessful
in retaining a contract to perform pathology services for a hospital in South
Florida. Based upon the remaining projected cash flow from this hospital
network, we determined that the intangible assets were impaired and recorded a
pre-tax non-cash charge of approximately $1.0 million. This hospital contract
accounted for approximately $800,000 of net revenue during 2000. Continuing
consolidation in the hospital industry may result in fewer hospitals or fewer
laboratories as hospitals move to combine their operations. Our contracts and
relationships with hospitals may be terminated or, in the case of contracts, may
not be renewed as their current terms expire.
Our business strategy emphasizes growth, which places significant demands on our
financial, operational and management resources and creates the risk of failing
to meet the growth expectations of investors.
Our growth strategy includes efforts to acquire and develop new practices,
develop and expand managed care and national clinical laboratory contracts and
develop new products, services, technologies and related alliances with third
parties. The pursuit of this growth strategy consumes capital resources, thereby
creating the financial risk that we will not realize an adequate return on this
investment. In addition, our growth may involve the acquisition of companies,
the development of products or services or the creation of strategic alliances
in areas in which we do not currently operate. This would require our management
to develop expertise in new areas, manage new business relationships and attract
new types of customers. The success of our growth strategy also depends on our
ability to expand our physician and employee base and to train, motivate and
manage employees. The success or failure of our growth strategy is difficult to
predict. The failure to achieve our stated growth objectives or the growth
expectations
31
of investors could disappoint investors and harm our stock price. We may not be
able to implement our growth strategy successfully or to manage our expanded
operations effectively and profitably.
We are pursuing business opportunities in new markets, such as genomics, which
adds uncertainty to our future results of operations and could divert financial
and management resources away from our core business.
As we pursue business opportunities in new markets, such as genomics, we
anticipate that significant investments and costs will be related to, and future
revenue may be derived from, products, services and alliances that do not exist
today or have not been marketed in sufficient quantities to measure accurately
market acceptance. Similarly, operating costs associated with new business
endeavors are difficult to predict with accuracy, thereby adding further
uncertainty to our future results of operations. We may experience difficulties
that could delay or prevent the successful development and introduction of new
products and services and such products and services may not achieve market
acceptance. Any failure by us to pursue new business opportunities successfully
could result in financial losses and could inhibit our anticipated growth. In
addition, the pursuit of new business endeavors could divert financial and
management resources away from our core business.
Ethical, social and legal issues concerning genomic research and testing may
result in regulations restricting the use of genomic testing or reduce the
demand for genomic testing products, which could impede our ability to achieve
our growth objectives.
Ethical, social and legal concerns about genomic testing and genomic
research could result in regulations restricting our or our customers'
activities or in only limited demand for those products. For example, the
potential availability of testing for some genomic predispositions to illness
has raised issues regarding the use and confidentiality of information obtained
from this testing. Some states in the United States have enacted legislation
restricting the use of information from some genomic testing, and the United
States Congress and some foreign governments are considering similar
legislation. The United States Food and Drug Administration, or FDA, has
subjected the commercialization of certain elements of genomic testing to
limited regulation. The federal Centers for Disease Control and Prevention has
published notice of its intent to revise the regulations under the Clinical
Laboratory Improvements Amendments, or CLIA, to specifically recognize and
regulate a genomic testing specialty. The Department of Health and Human
Services' Secretary's Advisory Committee on Genetic Testing advises the
Department of Health and Human Services as to various issues raised by the
development and use of genomic testing and has published preliminary
recommendations for increased participation on the part of the FDA and increased
regulation of genomic testing under CLIA. As a result of these activities, it is
likely that genomic testing will be subject to heightened regulatory standards.
Restrictions on our or our customers' use of genomic information or testing
products could impede our ability to broaden the range of testing services we
offer and to penetrate the genomic and genomic testing markets.
If we are unable to make acquisitions in the future, our rate of growth could
slow.
Much of our historical growth has come from acquisitions, and we continue
to pursue growth through the acquisition and development of laboratories and
pathology operations. However, we may be unable to continue to identify and
complete suitable acquisitions at prices we are willing to pay or to obtain the
necessary financing on acceptable terms. In addition, as we become a bigger
company, the amount that acquired businesses contribute to our revenue and
profits will likely be smaller on a percentage basis. We compete with other
companies to identify and complete suitable acquisitions. We expect this
competition to intensify, making it more difficult to acquire suitable companies
on favorable terms. For example, we may be unable to accurately and consistently
identify operations whose pathologists have strong professional reputations in
their local medical communities. Further, we may acquire operations whose
pathologists' individual marketing and other sales efforts do not produce a
profitable customer base. As a result, the businesses we acquire may not perform
well enough to justify our investment.
32
We may raise additional capital, which could be difficult to obtain at
attractive prices and which could cause us to engage in financing transactions
that adversely affect our stock price.
We need capital for both internal growth and the acquisition and
integration of new practices, products and services. Therefore, we may raise
additional capital through public or private offerings of equity securities or
debt financings. Our issuance of additional equity securities could cause
dilution to holders of our common stock and may adversely affect the market
price of our common stock. The incurrence of additional debt could increase our
interest expense and other debt service obligations and could result in the
imposition of covenants that restrict our operational and financial flexibility.
Additional capital may not be available to us on commercially reasonable terms
or at all. The failure to raise additional needed capital could impede the
implementation of our operating and growth strategies.
The success of our growth strategy depends on our ability to adapt to new
markets and effectively integrate newly acquired operations.
Our expansion into new markets will require us to maintain and establish
payor and customer relationships and to convert the patient tracking and
financial reporting systems of new operations to our systems. Significant delays
or expenses with regard to this process could materially harm the integration of
additional operations and our profitability. The integration of acquisitions
also requires the implementation and centralization of purchasing, accounting,
sales and marketing, payroll, human resources, management information systems,
cash management, risk management and other systems, which may be difficult,
costly and time-consuming. Accordingly, our operating results, particularly in
fiscal quarters immediately following an acquisition, may be adversely affected
while we attempt to complete the integration process. We may encounter
significant unanticipated costs or other problems associated with the future
integration into our combined network. Our expansion into new markets may
require us to comply with present or future laws and regulations that may differ
from those to which we are currently subject. Failure to meet these requirements
could materially impede our growth objectives or materially harm our business.
We may inherit significant liabilities from operations that we have acquired or
acquire in the future.
We perform due diligence investigations with respect to potential
liabilities of acquisitions and typically obtain indemnification with respect to
liabilities from the sellers. Nevertheless, undiscovered claims may arise and
liabilities for which we become responsible may be material and may exceed
either the limitations of any applicable indemnification provisions or the
financial resources of the indemnifying parties. Claims or liabilities of
acquired and affiliated operations may include matters involving compliance with
laws, including health care laws. While we believe, based on our due diligence
investigations, that the operations of our operations prior to their acquisition
were generally in compliance with applicable health care laws, it is
nevertheless possible that such operations were not in full compliance with such
laws and that we will become accountable for their non-compliance. We have, from
time to time, identified certain past practices of acquired operations that do
not conform to our standards. A violation of applicable health care laws,
whether or not the violation occurred prior to our acquisition, could result in
civil and criminal penalties, exclusion of the physician, the operation or us
from participation in Medicare and Medicaid programs and loss of a physician's
license to practice medicine. Significant fines and other penalties could cause
liquidity problems and adversely affect our results of operations. Exclusion
from participation in government payor programs, which represented 21% of our
collections in the first six months of 2002, would eliminate an important source
of revenue and could materially harm our business.
We have significant contingent liabilities payable to many of the sellers of
practices that we have acquired.
In connection with our practice acquisitions, we typically agree to pay the
sellers additional consideration in the form of contingent debt obligations,
payment of which depends upon the practice achieving specified profitability
criteria over periods ranging from three to five years after the acquisition.
The amount of these contingent payments cannot be determined until the
contingency periods terminate and achievement of the profitability criteria is
determined. As of June 30, 2002, if the maximum criteria for the contingency
payments with respect to all prior acquisitions were achieved, we would be
obligated to make payments, including principal and interest, of
33
approximately $142.4 million over the next three to five years. This amount
could increase significantly as we continue selectively to acquire new
practices. Lesser amounts would be paid if the maximum criteria were not met.
Although we believe we will be able to make such payments from internally
generated funds or proceeds of future borrowings, it is possible that such
payments could cause significant liquidity problems for us. We continue to use
contingent notes as partial consideration for acquisitions and affiliations.
We have recorded a significant amount of intangible assets, which may never be
realized.
Our acquisitions have resulted in significant increases in net identifiable
intangible assets and goodwill. Net identifiable intangible assets, which
include hospital contracts, physician client lists, management service
agreements and laboratory contracts acquired in acquisitions were approximately
$254.1 million at June 30, 2002, representing approximately 40% of our total
assets. Net identifiable intangible assets are recorded at fair value on the
date of acquisition and are being amortized over periods ranging from 10 to 40
years. Goodwill, which relates to the excess of cost over the fair value of net
assets of businesses acquired, was approximately $250.1 million at June 30,
2002, representing approximately 39% of our total assets. On an ongoing basis,
we make an evaluation to determine whether events and circumstances indicate
that all or a portion of the carrying value of intangible assets may no longer
be recoverable, in which case an additional charge to earnings may be necessary.
For example, during the years ended December 31, 2000 and 2001, we recorded
asset impairment charges to intangible assets in the amount of $9.6 million and
$3.8 million, respectively. We may not ever realize the full value of our
intangible assets. Any future determination requiring the write-off of a
significant portion of intangible assets could materially harm our results of
operations for the period in which the write-off occurs, which could adversely
affect our stock price.
Our business is highly dependent on the recruitment and retention of qualified
pathologists.
Our business is dependent upon recruiting and retaining pathologists,
particularly those with subspecialties, such as dermatopathology,
hematopathology, immunopathology and cytopathology. While we have been able to
recruit, principally through acquisitions, and retain pathologists, we may be
unable to continue to do so in the future as competition for the services of
pathologists increases. In addition, we may have to modify the economic terms of
our relationships with pathologists in order to enhance our recruitment and
retention efforts. Because it may not be possible to recover increased costs
through price increases, this could materially harm our profitability. The
relationship between the pathologists and their respective local medical
communities is important to the operation and continued profitability of each
practice. Loss of one of our pathologists for any reason could lead to the loss
of hospital contracts or other sources of revenue that depend on our continuing
relationship with that pathologist. Our revenues and earnings could be adversely
affected if a significant number of pathologists terminate their relationships
with our practices or become unable or unwilling to continue their employment,
or if a number of our non-competition agreements with physicians are terminated
or determined to be invalid or unenforceable. For example, in 2001, the two
pathologists in our Birmingham, Alabama practice terminated their employment
with us and opened their own pathology lab. As a result, we closed an operating
lab in Alabama. We have implemented a strategy to retain those customers and
service them through other AmeriPath facilities, including another lab we
subsequently acquired in Alabama. As of December 31, 2001, we had been unable to
retain these customers, and therefore recorded a non-cash asset impairment
charge of $3.8 million. We continue to aggressively market in Alabama and expect
to be successful in gaining some of these customers back during 2002.
Enactment of proposals to reform the health care industry may restrict our
existing operations, impose additional requirements on us, limit our expansion
or increase our costs of regulatory compliance.
Federal and state governments periodically focus significant attention on
health care reform. It is not possible to predict which, if any, proposal will
be adopted. It is possible that the health care regulatory environment will
change so as to restrict our existing operations, impose additional requirements
on us or limit our expansion. Costs of compliance with changes in government
regulations may not be subject to recovery through price increases.
34
Competition from other providers of pathology services, including national
clinical labs, may materially harm our business.
Health care companies such as hospitals, national clinical laboratories,
third-party payors and health maintenance organizations may compete with us in
the employment of pathologists and the management of pathology practices. We
also expect to experience increasing competition in the provision of pathology
and cytology diagnostic services from other anatomic pathology practices,
companies in other health care industry segments, such as other hospital-based
specialties, national clinical laboratories, large physician group practices or
other pathology physician practice management companies. In particular, national
clinical laboratories who presently refer business to us may seek to develop the
capacity to do this business in-house. For example, Quest may internalize
anatomic pathology work previously performed by our operations in various
locations. Some of our competitors may have greater financial and other
resources than we, which could further intensify competition. Increasing
competition may erode our customer base, reduce our sources of revenue, cause us
to reduce prices or enter into a greater number of capitated contracts in which
we take on greater pricing risks, or increase our marketing and other costs of
doing business. Increasing competition may also impede our growth objectives by
making it more difficult or more expensive for us to acquire or affiliate with
additional pathology practices.
We are subject to significant professional or other liability claims, and we
cannot assure you that insurance coverage will be available or sufficient to
cover such claims.
Our business entails an inherent risk of claims of physician professional
liability or other liability for acts or omissions of our physicians and
laboratory personnel or of hospital employees who are under the supervision of
our hospital-based pathologists. We and our physicians periodically become
involved as defendants in medical malpractice and other lawsuits, some of which
are currently ongoing, and are subject to the attendant risk of substantial
damage awards. While we believe that we have a prudent risk management program,
including professional liability and general liability insurance coverage as
well as agreements from third parties, such as hospitals and national clinical
laboratories, to indemnify or insure us, it is possible that pending or future
claims will not be covered by or will exceed the limits of our risk management
program, including the limits of our insurance coverage or applicable
indemnification provisions, or that third parties will fail or otherwise be
unable to comply with their obligations to us. While we believe this practice is
routine, in a number of pending claims our insurers have reserved their rights
to deny coverage. In addition, we are currently in a dispute with our former
medical malpractice carrier on an issue related to the applicability of excess
insurance coverage. If we do not prevail, a gap of several months in our excess
insurance coverage may exist for a period in which significant claims have been
made. It is also possible that the costs of our insurance coverage will rise
causing us either to incur additional costs or to further limit the amount of
coverage we have. In addition, our insurance does not cover all potential
liabilities arising from governmental fines and penalties, indemnification
agreements and certain other uninsurable losses. For example, from time to time
we agree to indemnify third parties, such as hospitals and national clinical
laboratories, for various claims that may not be covered by insurance. As a
result, we may become responsible for substantial damage awards that are
uninsured. We are currently subject to indemnity claims which, if determined
adversely to us, could result in substantial uninsured losses.
In December 2001, the Company was notified by its medical malpractice
carrier that they will no longer be underwriting medical malpractice insurance
and placed the Company on non-renewal status effective July 1, 2002. The Company
evaluated other potential carriers for medical malpractice and conducted a
feasibility study of a captive insurance company. In late June 2002, we
completed the renewal of our medical malpractice insurance program for the
policy year beginning July 1, 2002. In connection with our renewal we were
unable to obtain traditional lines of coverage similar to previous coverage. As
a result, we formed a captive insurance company to partially self-insure our
medical malpractice risk. Under the captive structure we will retain more risk
for medical malpractice costs, including settlements and claims expense, than
our previous coverage. The captive insurance company and excess policies provide
malpractice insurance on a per-claim basis. We have no aggregate excess stop
loss protection. Based on actuarial estimates, our medical malpractice costs for
the policy year beginning July 1, 2002 will increase $6.0 to $8.0 million over
the previous policy year. Although we have estimated this increase based on
actuarial studies, there can be no assurance that actual costs will not exceed
our estimates. Actual costs, including settlement costs, claims expenses and
accrual for incurred but not reported losses, may be significantly higher than
our estimates depending on the frequency and severity of our actual claims
experience. There can be no
35
assurance the Company will be able to maintain medical malpractice insurance on
terms consistent with our current coverage, which may increase our cost.
We depend on certain key executives, the loss of whom could disrupt our
operations, cause us to incur additional expenses and impede our ability to
expand our operations.
Our success is dependent upon the efforts and abilities of our key
management personnel, particularly James C. New, our Chairman and Chief
Executive Officer, Brian C. Carr, our President, Gregory A. Marsh, our Vice
President and Chief Financial Officer, and Dennis M. Smith, Jr., M.D., our
Executive Vice President of Genomic Strategies and Medical Director. It would be
costly, time consuming and difficult to find suitable replacements for these
individuals. The need to find replacements combined with the temporary loss of
these key services could also materially disrupt our operations and impede our
growth by diverting management attention away from our core business and growth
strategies.
We depend on numerous complex information systems and any failure to
successfully maintain those systems or implement new systems could materially
harm our operations.
We depend upon numerous information systems to provide operational and
financial information on our operations, provide test reporting to physicians
and handle our complex billing operations. We currently have several major
information technology initiatives underway, including the integration of
information from our operations. No assurance can be given that we will be able
to enhance existing and/or implement new information systems that can integrate
successfully the disparate operational and financial information systems of our
operations. In addition to their integral role in helping our operations realize
operating efficiencies, such new systems are critical to developing and
implementing a comprehensive enterprise-wide management information database. To
develop such an integrated network, we must continue to invest in and administer
sophisticated management information systems. We may experience unanticipated
delays, complications and expenses in implementing, integrating and operating
such systems. Furthermore, our information systems may require modifications,
improvements or replacements as we expand and as new technologies become
available. Such modifications, improvements or replacements may require
substantial expenditures and may require interruptions in operations during
periods of implementation. Moreover, implementation of such systems is subject
to the availability of information technology and skilled personnel to assist us
in creating and implementing the systems. The failure to successfully implement
and maintain operation, financial, test reports, billing and physician practice
information systems could substantially impede the implementation of our
operating and growth strategies and the realization of expected operating
efficiencies.
Failure to timely or accurately bill for our services may have a substantial
negative impact on our revenues, cash flow and bad debt expense.
Billing for laboratory testing services is complicated. The industry
practice of performing tests in advance of payment and without certainty as to
the outcome of the billing process may have a substantial negative impact on our
revenues, cash flow and bad debt expense. We bill various payors, such as
patients, insurance companies, Medicare, Medicaid, and national clinical
laboratories, all of which have different billing requirements. In addition, the
billing information requirements of the various payors have become increasingly
stringent, typically conditioning reimbursement to us on the provision of proper
medical necessity and diagnosis codes by the requisitioning client. This
complexity may increase our bad debt expense, due primarily to several
non-credit related issues such as missing or incorrect billing information on
test requisitions.
Among many other factors complicating our billing are:
. disputes between payors as to which party is responsible for payment;
. disparity in coverage among various payors; and
36
. the difficulty of adherence to specific compliance requirements,
diagnosis coding and procedures mandated by various payors.
The complexity of laboratory billing also tends to cause delays in our cash
collections. Confirming incorrect or missing billing information generally slows
down the billing process and increases the aging of accounts receivable. We
assume the financial risk related to collection, including the potential
uncollectability of accounts and delays due to incorrect and missing information
and the other complex factors identified above.
Our stock price is volatile and the value of your investment may decrease for
various reasons, including reasons that are unrelated to the performance of our
business.
There has been significant volatility in the market price of securities of
health care companies that often has been unrelated to the operating performance
of such companies. In fact, since January 1, 2000, our common stock, which
trades on the NASDAQ National Market, has traded from a low of $7.00 per share
to a high of $37.16 per share. We believe that various factors, such as
legislative and regulatory developments, investigations by regulatory bodies or
third-party payors, quarterly variations in our actual or anticipated results of
operations, lower revenues or earnings than those anticipated by securities
analysts, the overall economy and the financial markets could cause the price of
our common stock to fluctuate substantially. For example, in the fourth quarter
of 1998, our stock price declined significantly as a result of an announcement
by the government of its intent to seek recovery of amounts allegedly improperly
reimbursed to us under Medicare. Although the claim was resolved to our
satisfaction and resulted only in a small fine, similar investigations may be
announced having the same effect on the market price of our stock. In addition,
securities class action claims have been brought against companies whose stock
prices have been volatile. Several such suits were brought against us, and
subsequently dismissed, as a result of the decline in our stock price described
above. This kind of litigation could be very costly and could divert our
management's attention and resources. Any adverse determination in this type of
litigation could also subject us to significant liabilities, any or all of which
could materially harm our liquidity and capital resources.
Certain provisions of our charter, by-laws and Delaware law may delay or prevent
a change of control of our company.
Our corporate documents and Delaware law contain provisions that may enable
our board of directors or management to resist a change of control of our
company. These provisions include a staggered board of directors, limitations on
persons authorized to call a special meeting of stockholders and advance notice
procedures required for stockholders to make nominations of candidates for
election as directors or to bring matters before an annual meeting of
stockholders. We also have a rights plan designed to make it more costly and
more difficult to gain control of our company. These anti-takeover defenses
could discourage, delay or prevent a change of control. These provisions could
also discourage proxy contests and make it more difficult for you and other
stockholders to elect directors and cause us to take other corporate actions. In
addition, the existence of these provisions, together with Delaware law, might
hinder or delay an attempted takeover other than through negotiations with our
board of directors.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
INTEREST RATE RISK
We are subject to market risk associated principally with changes in
interest rates. Interest rate exposure is principally limited to the amount
outstanding under the credit facility of $98.6 million at June 30, 2002.
Currently the balances outstanding under the credit facility are at floating
rates. Based on the outstanding balance of $98.6 million, each quarter point
increase or decrease in the floating rate changes interest expense by $245,000
per year. In the future, the Company may evaluate entering into interest rate
swaps, involving the exchange of floating for fixed rate interest payments, to
reduce interest rate volatility.
37
PART II--OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
During the ordinary course of business, the Company has become and may in
the future become subject to pending and threatened legal actions and
proceedings. The Company may have liability with respect to its employees and
its pathologists as well as with respect to hospital employees who are under the
supervision of the hospital based pathologists. The majority of the pending
legal proceedings involve claims of medical malpractice. These claims are
generally covered by insurance. Based upon investigations conducted to date, the
Company believes the outcome of such pending legal actions and proceedings,
individually or in the aggregate, will not have a material adverse effect on the
Company's financial condition, results of operations or liquidity. If the
Company is ultimately found liable under these medical malpractice claims, there
can be no assurance that the Company's medical malpractice insurance coverage
will be adequate to cover any such liability. The Company may also, from time to
time, be involved with legal actions related to the acquisition of and
affiliation with physician practices, the prior conduct of such practices, or
the employment (and restriction on competition of) physicians. There can be no
assurance that any costs or liabilities for which the Company becomes
responsible in connection with such claims or actions will not be material or
will not exceed the limitations of any applicable indemnification provisions or
the financial resources of the indemnifying parties.
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
Recent Sales of Unregistered Securities - In connection with acquisitions
completed during the year 2002, the Company issued the following shares of
common stock to the owners of the following acquired business as partial
consideration for the acquired businesses:
Location Effective Date Shares Issued
--------------------------------------------------------
Empire Pathology Irvine, CA April 1, 2002 11,570
O'Quinn Medical Pathology Association Augusta, GA July 2, 2002 96,695
The Company relied upon the exemption from registration contained in
Section 4(2) of the Securities Act of 1933 because these issuances did not
involve any public offering.
ITEM 4. SUBMISSION OF MATTERS TO VOTE OF SECURITY HOLDERS
The Company's Annual Meeting of Shareholders was held on May 2, 2002. The
matters voted on at the Annual Meeting and the tabulation of votes on such
matters are as follows:
(a) Election of Class II Directors.
Name Number Voting For Against or Withheld
------------------------ ------------- ---------- -------------------
Brian C. Carr 24,164,920 22,122,409 2,042,511
Haywood D. Cochrane, Jr. 24,164,920 23,934,242 230,678
E. Martin Gibson 24,164,920 23,941,708 223,212
The remaining directors whose terms continue after the meeting were James C.
New, James T. Kelly, Dennis M. Smith, Jr., M.D., and C. Arnold Renschler, M.D.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
38
(a) Exhibits
None.
(b) Reports on Form 8-K
A Report on Form 8-K, dated April 4, 2002, was filed by the Company with
the Securities and Exchange Commission on April 4, 2002, reporting that on
April 1, 2002, the Audit Committee of AmeriPath, Inc. recommended to its
Board of Directors and the Board of Directors approved the engagement of
Ernst and Young as its independent auditors for the year ending December 31,
2002 to replace the firm of Deloitte & Touche LLP (Deloitte). Deloitte was
dismissed on April 1, 2002 as auditors of the Company effective upon the
completion of the required procedures and communications in connection with
Deloitte's audit of the financial statements for the year ended December 31,
2001. The reports of Deloitte on the Company's financial statements for the
past two years did not contain an adverse opinion or a disclaimer of opinion
and were not qualified or modified as to uncertainty, audit scope, or
accounting principles. In connection with the audits of the Company's
financial statements for each of the two years in the period ended December
31, 2001, and in the subsequent interim period, through the date of
Deloitte's termination on April 1, 2002, there were no disagreements with
Deloitte on any matters of accounting principles or practices, financial
statement disclosure, or auditing scope and procedures which, if not resolved
to the satisfaction of Deloitte, would have caused Deloitte to make reference
to the matter in their report. The Company had requested Deloitte to furnish
it a letter addressed to the Commission stating whether it agrees with the
above statements. A copy of that letter, dated April 12, 2002 is filed as
Exhibit 16 to the Form 8-K A.
The report on Form 8-K, dated April 4, 2002, was subsequently amended on
a current report on Form 8-K/A, dated April 1, 2002, as filed by the Company
with the Securities and Exchange Commission on April 15, 2002.
A Current Report on Form 8-K, dated July 1, 2002, was filed by the
Company with the Securities and Exchange Commission on July 15, 2002,
reporting an increase in malpractice costs and the proposed revisions to
Medicare payment under the physician fee schedule for 2003.
A copy of the press release, dated July 2, 2002 is filed as Exhibit 99.1
to the Form 8-K.
39
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
AMERIPATH, INC.
Date: August 14, 2002
/s/ James C. New
By:
James C. New
Chairman and
Chief Executive Officer
Date: August 14, 2002
/s/ Gregory A. Marsh
By:
Gregory A. Marsh
Vice President and
Chief Financial Officer
40